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Prof. dr. B.P.F. Lelieveldt
Co-promotores Dr. E.L. Kaijzel
Dr. J. Dijkstra
Overige Leden Prof. dr. M. Hoehn, Max Planck Instituut, Keulen, Duitsland
Prof. dr. F. Ossendorp
Prof. dr. S.E. Papapoulos
The studies presented in this thesis have been financially supported by the Dutch Cancer
Society, Koningin Wilhelmina Fonds (grant UL2007-3801) and the 6th FP EU grants EMIL
(LSH-CT-2004-503569) and DiMI (LSBH-CT-2005-512146) and ctmm project musis.
Financial support for the costs associated with the publication of this thesis was received
from the European Society for Molecular Imaging, Caliper Life Sciences, Bontius Stichting
Doelfonds Beeldverwerking, J.E. Jurriaanse Stichting and Li-Cor Biosciences.
But there is another alchemy, operative and practical,
which teaches how to make the noble metals and colours
and many other things better and more abundantly by
art than they are made in nature. And science of this
kind is greater than all those preceding because it pro-
duces greater utilities. For not only can it yield wealth
and very many other things for the public welfare, but it
also teaches how to discover such things as are capable
of prolonging human life for much longer periods than
can be accomplished by nature . . . Therefore this science
has special utilities of that nature, while nevertheless it
confirms theoretical alchemy through its works.
Roger Bacon
Opus Tertium (1266-1268), Chapter 12
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Breast Cancer; a Perspective
Over the last decades, the prognosis of breast cancer has been much improved (Figure
1.1). For instance, the five year survival rate based on all cases registered by the
United States Surveillance Epidemiology and End Results (SEER) program in 2001–
2007 was 89% compared to 60% in the 1950s.1 Based on the same SEER data,
approximately 12% of the women born in the U.S. today will eventually develop
breast cancer during their lifetime.
The chance of survival depends strongly on the stage of the disease at the mo-
ment of diagnosis. The 5 year survival rate of breast cancer patients with localized
disease is 98% compared to only 23% for patients with distant metastases. This
shows that a large number of patients carrying distant metastases cannot be cured.
Consequently, treatment of these patients is mainly palliative, aimed at prolonging
life and improving the quality of life.1,2
Autopsy revealed bone metastases in approximately 70% off all patients who
died of breast cancer.3,4 This preference of breast cancer to metastasize to bone, a
characteristic shared with prostate cancer, has already been noted by Stephen Paget
in 1889. As a metaphor describing this characteristic he wrote that “When a plant
goes to seed, its seeds are carried in all directions; but they can only live and grow if
they fall on congenial soil”.5 This so called seed and soil hypotheses still holds true
today, be it slightly rephrased to fit present day scientific knowledge.
Bone metastases are especially difficult to treat due to a strong positive feedback
loop between the tumor and the bone micro-environment.6 Tools to follow treatment
response in a pre-clinical setting of both tumor and bone related processes such as tu-
mor growth, angiogenesis, expression of enzymes and signaling molecules, osteolysis
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Figure 1.1: Five-year survival of breast cancer patients by year of diagnosis. The five-year
survival of all female breast cancer patients has been steadily increasing over the last decades.
This can be explained by better treatments on one hand and earlier diagnosis due to extensive
mammography screening on the other hand.1
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tases. Only approaches that are capable of following all of these processes will enable
a researcher to get a complete understanding in disease progression and treatment
efficacy.
Molecular imaging has become one of the main tools in cancer research. The
possibility to perform both structural and functional imaging make molecular imaging
modalities an attractive research tool. The integrated data handling of different
imaging modalities and their possible role in cancer research are discussed within
this thesis. The described approaches have been applied in the evaluation of a new
compound, ENMD-1198, as possible beneficial compound in the treatment of bone
metastases in a pre-clinical mouse model.
Metastatic Bone Disease
Before evaluating the use of various imaging approaches in the field of bone metas-
tases research, it is important to have a general understanding of the biology and
pathophysiology of this specific type of metastases. Both breast and prostate cancer
have a strong preference to metastasize to bone. In the bone micro-environment,
breast cancer is more likely to result in osteolytic lesions while prostate cancer re-
sults mainly in osteoblastic lesions, but also mixed lesions exist in some cases.7,8 The
complications caused by bone metastasis are vast; osteolytic lesions may result in
severe bone pain, fracture, life-threatening hypercalcaemia and nerve compression,
whereas, osteoblastic lesions can result in severe bone pain or fracture due to the
reduced quality of the bone.
There is a multitude of crucial processes during bone metastatic growth. These
include tumor growth and tumor–stroma interactions by direct contact and through
signaling molecules (reviewed by Lorusso et al.9 and Mundy10). The interactions
and signaling between the tumor and its direct surroundings result in local pro-
angiogenic signaling (reviewed by Voorzanger-Rousselot et al.11 and Guise et al.12),
local activation and infiltration of the innate immune system and local suppression of
the adaptive immune system (reviewed by Lin et al.13). All of these processes have
a positive feedback on tumor growth. Moreover, the skeletal metastatic sites are
often characterized by a distortion of the delicate balance in bone turnover leading
to osteolytic and/or osteoblastic lesions at the metastatic tumor site.
A Vicious Cycle
The bone matrix holds an abundant store of growth factors, which are released
during bone resorption. Many different cell types are involved in the process of bone
metastatic growth: tumor cells, endothelial cells and stromal cells, plus the bone
specific osteoblasts and osteoclasts and their precursors. Each of these cell types
fulfill their own key role in the context of bone metastasis.
Once settled in the bone micro-environment, breast cancer cels are capable of
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Figure 1.2: Schematic representation of the vicious cycle of bone metastasis. Tumor cells stim-
ulate Osteoblasts and stromal cells to express RANKL by producing osteolytic factors as
PTHrP, IL-1, IL-6 and IL-11. These factors lead to a downregulation in OPG expression, an
inhibitor of RANKL. In turn, RANKL results in increased osteoclastogenesis and osteoclast
survival. Mineralized bone matrix is rich in cytokines and growth factors including TGF-β.
These factors are released in the bone marrow space upon bone resorption by osteoclasts.
In turn, these factors stimulate tumor cell survival, growth, and production of PTHrP and
other osteolytic factors which further stimulate osteoclastic resorption. In addition, bone
metastases are generally hypoxic leading to an upregulation of HIF-1α and secretion of
VEGF, a strong pro-angiogenic factor. CEPs are attracted by leaky tumor vasculature and
further stimulates angiogenesis. Tumors recruit Treg cells via a mechanism which is largely
unknown. Treg cells inhibit possible immune reactions against the tumor through the down
regulation of T & B effector and helper cells.6,10,14
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insulin-like growth factors (IGFs), transforming growth factor-β (TGF-β) and parathy-
roid hormone-related protein (PTHrP), which in themselves have an effect on bone.7,15
PTHrP is a signaling molecule involved in mammary gland development and lacta-
tion, hence, its strong presence both in the healthy breast as well as in breast can-
cer. In addition, PTHrP is involved in many other processes as signaling molecule,
amongst which the maintenance of a calcium homeostasis.16–18 These multiple func-
tions of PTHrP are at the core of the pathogenesis of osteolytic bone metastases of
breast cancer.
PTHrP, released locally in the bone by metastases, stimulates the expression of
receptor activator for nuclear factor-κB ligand (RANKL) on neighboring bone mar-
row stromal cells and osteoblasts.10 RANKL signaling stimulates the maturation
of osteoclasts from RANK positive precursor cells. Moreover, RANKL prolongs the
survival of mature, active, osteoclasts.19 Osteoclasts resorb the mineralized bone ma-
trix, which in turn causes the release and activation of growth factors and cytokines
present in the bone. TGF-β is such a factor which is highly present in bone.20,21
The released TGF-β stimulates tumor cells to produce more osteolytic factors
(PTHrP, IL-6, IL-11) that can, in turn, further stimulate osteoclastic resorption and
increase the TGF-β release from bone.6,20,22 This feed-forward stimulation of osteo-
clastic bone resorption is referred to as the “vicious cycle” of bone metastasis (Figure
1.2).15,22–24 The strong positive feedback between bone destruction and metastatic
growth makes these lesions nearly impossible to treat.10,14 The local bone destruction
is the main cause or morbidity in metastatic bone disease.
Tumor Angiogenesis
Tumors cannot grow without sufficient blood supply making angiogenesis a critical
process in tumor growth. In the adult, angiogenesis is a tightly regulated process
occurring almost exclusively during wound healing and in ischemic areas. However, at
a certain point during tumor growth there is a shift of balance towards angiogenesis.
This shift has been called the “angiogenic switch”, a result of crosstalk between the
tumor and surrounding healthy tissue.25
In the case of bone metastases, angiogenesis is strongly driven by hypoxia. Hy-
poxia and the stabilization of hypoxia inducible factor-1α (HIF-1α) as a key initiators
of (tumor-)angiogenesis has been studied extensively and reviewed by Liao and John-
son.26 VEGF is one of the downstream targets of hypoxia signaling and the main
factor involved in pro-angiogenic signaling.27 Most of the vasculogenic and angiogenic
effects of VEGF are mediated through the VEGF receptor 1 (VEGFR1, FLT-1) and
VEGF receptor 2 (VEGFR2, Flk-1) expressed on endothelial cells.28 During an-
giogenesis, including tumor angiogenesis, both VEGF and VEGFR2 expression are
locally upregulated.29,30
The one sided pro-angiogenic, mainly VEGF mediated, signaling leads to the
formation of an abnormal vascular network. The newly formed vessels are leaky, tor-
tuous and often lack pericytes and a basement membrane.31,32 Leaky, poorly formed,
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vasculature and high levels of VEGF attract circulating endothelial progenitor cells
(CEPs). These cells are able to differentiate into endothelial cells and are normally
involved in vessel repair, angiogenesis and neo-vascularization, adding up to the al-
ready existing pro-angiogenic environment (Figure 1.2).33,34
Molecular Imaging
Molecular imaging is the term used to describe a wide range of imaging tools and
techniques that enable the visualization of molecular processes and interactions (func-
tional imaging) or structures and micro-architecture (structural imaging). Molecular
imaging modalities can be based on light (e.g. optical imaging), on the use of ra-
dioactive tracers (e.g. PET and SPECT), on the use of ultrasound or on differences
in magnetic resonance (e.g. MRI). These functional imaging modalities can be com-
bined with structural imaging modalities which provide more anatomical detail such
as radiography or computed tomography (CT).
When performing research on bone metastases, it is important to follow both
structural and functional developments in and around the tumor. Structural imag-
ing modalities are used to follow diseased induced changes to the skeleton whereas
functional imaging is to follow processes such as matrix degeneration, tumor angio-
genesis and tumor growth. The non-invasive character of optical imaging, imaging
modalities based on detection of light, makes it possible to follow animals over time
throughout the experimental period.
Whole Body Optical Imaging
Optical imaging of cancer presents a challenge because tumor cells usually do not
have a specific optical quality that clearly distinguishes them from normal tissue.
However, the field of whole body optical imaging has been transformed over the
last decades by improvements in camera detection systems as well as better tools for
making clonal cell lines or transgenic animal models with light-generating capabilities
or specific fluorescent properties.
The term optical imaging includes all of the imaging techniques based on the
detection of photons with wavelengths in the ultraviolet, visible, near-infrared and
infrared parts of the spectrum. These photons are emitted from living cells, tis-
sues or animals through either bioluminescence or fluorescence. As a result, optical
imaging can be divided in: bioluminescence imaging (BLI) and fluorescence imaging
(FLI). Despite the similarities in their applications, BLI and FLI both have their
own characteristics, strengths and weaknesses such as differences in availability, sen-
sitivity, signal to noise ratio (SNR) and interference by background emission from
tissues.35–38
The choice of tools, such as whether to use FLI or BLI, is determined by the
questions needing to be addressed, e.g. FLI allows total cells in vivo to be measured
as well as in vitro and ex vivo analysis to be performed whereas BLI often gives an
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indication of metabolizing cell activity. Therefore, BLI has evolved into a standard
modality in pre-clinical research to follow tumor growth non-invasively over time.
X-rays and µCT
X-rays dominated the field of skeletal imaging ever since Rontgen’s publication of a
photo of his wife’s hand and various other shadow images in Science back in 1896.39–41
The subsequent work of people like Alessandro Vallebona and William Watson formed
the basis of X-ray tomography. It is during the 1970s that X-ray-based imaging
underwent revolutionary changes after advances in digital computing enabled the
development of CT by Godfrey Hounsfield.42,43
Radiographs of small animals are made in the same way as their human counter-
part. The technique is not much different from the method described by Röntgen.
The subject is placed between a concealed photographic film or digital X-ray camera
and an X-ray point source. The recorded image is a two dimensional (2D) shadow
projection of the subject.
Relatively new are specialized small animal µCT scanners. These machines can
produce high resolution three dimensional (3D) datasets of in vivo and ex vivo speci-
mens. In general, 3D methodologies are preferable over their 2D counterparts as they
give a better approximation of the real life situation. Moreover, µCT can potentially
be used to quantify osteoblastic lesions as well as osteolytic lesions, something that is
not possible with radiography. However, data analysis of 3D datasets can be tedious
and only few standardized protocols for data analysis are in place since the imaging
techniques are relatively new.44–47
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Contribution and Outline of this Thesis
The aim of this work was to develop methods to measure structural changes in the
skeleton using µCT. In addition, these new methods should be able to quantify biolog-
ically relevant changes. In order to do this, normalized methods to analyze µCT scans
and perform quantitive measurements within these datasets are described in this the-
sis. These techniques were combined with a biological angiogenesis assay and used
as research tools in a study comparing various different combination treatments of
bone metastases.
Chapter 2 describes a manual µCT based method to asses specific changes in bone
volume. The method allows the user to select normalized volumes of interest based
on manual input. In addition, the user can generate normalized cross sections and
longitudinal sections for side-by-side presentations, comparison of cortical thickness
and validation of histological findings.
Chapter 3 describes an automated µCT based method to assess disease induce changes
in bone volume and thickness. The segmentation and volume measurements are fully
automated in order to minimize observer bias. The segmentation algorithm is able to
find the region of interest in whole-body rodent µCT scans, regardless of the animal
posture during the scan. The exact location of volumetric changes can be asses using
automatically generated color coded cortical thickness maps.
Chapter 4 gives an overview of the advances made by the LUMC departments of
Endocrinology and Radiology - Image Processing (LKEB) in multi-modality molec-
ular imaging with an emphasis on µCT. This puts Chapters 2 and 3 in a broader
perspective by linking µCT to other imaging modalities.
Chapter 5 describes an angiogenesis assay. The essay enables the differentiation be-
tween anti-angiogenic and vascular disrupting properties of compounds. In addition,
the assay will indicate the main mechanism underlying the anti-angiogenic properties
Chapter 6 discusses the efficacy of the suggested combination treatment consisting
of ENMD-1198, “metronomic” cyclophosphamide and bisphosphonates. In addition,
this chapter is exemplary on how the described angiogenesis assay, µCT quantification
techniques, radiographs and optical imaging can be combined in a set of experiments
to answer biological questions and assess treatment efficacy.
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Abstract
Quantification of osteolytic lesions in bone is pivotal in the research of metastatic
bone disease in small animal models. Osteolytic lesions are quantified using two di-
mensional X-ray photographs, which often neglects to take into account any changes
in three dimensional structure. Furthermore, measurement errors are inadvertently
introduced when a region of interest with predefined dimensions is used during
µCT analysis. To study osteolytic processes, a normalized method of selecting a
region of interest is required. Here we describe a new method to select volumes of
interest in a normalized way regardless of curvature, fractures or dislocations within
the bone. In addition, this method enables the user to visualize normalized cross-
sections in an exact 90◦ angle or along the longitudinal axis of bone, at any given
point. As a result, the user can compare measurements of diameter, volume and
structure between different bones in a normalized manner.
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Introduction
Certain types of cancer preferentially metastasize to bone. In cases of breast can-
cer, post mortem examination revealed that over 70% of the patients carried bone
metastases.1 Bone metastases are the cause of severe morbidity.2–4 As a result, much
research is being conducted toward an optimal treatment regimen. Therefore, quan-
tification of osteolytic lesion size and treatment evaluation in small animal models are
pivotal for preclinical research in being able to characterize metastatic bone disease.
At present, osteolytic lesions are quantified using two dimensional (2D) radio-
graphs.5,6 The scoring of radiographs is performed by manual drawing of a region
of interest (ROI) around the lesion, a method prone to observer bias. This proce-
dure cannot be automated because of high variability of shape and grey-values of
the bones and lesions. The grey-value intensity of the lesion depends heavily on the
location of the lesion and the chance of multiple lesions being projected on top of
each other. The shape of the bone itself can be altered drastically due to fractures or
the bone can even be partially destroyed in case of severe osteolytic lesions, making
the reproducible selection of a ROI more difficult. Small lesions and subtle changes
in bone thickness are not visible or easily overlooked.
µCT scans provide three dimensional (3D) structural information which allows a
more exact assessment of the disease-induced changes. In contrast to conventional
radiography, µCT scans can be used to quantify both the decrease in bone volume
in case of osteolysis as well as the increase in bone volume in case of osteoblastic
lesions. However, analysis of µCT scans is difficult and time consuming.
A normalized method of selecting a region of interest is required in order to study
volumetric changes. The murine tibia for instance, is slightly curved in a healthy
state. This curved shape makes it impossible to make a µCT scan composed entirely
of slices that are perpendicular to the center-line of the bone. In the case of severe
osteolysis, parts of the bone might be missing or fractured increasing the complexity
of volume of interest (VOI) selection. Therefore, the µCT scan must be reformatted
in order to be able to perform a normalized selection of a VOI independent of the
scan orientation.
Here we describe a new method to reformat µCT scans and select a VOI in a
normalized way regardless of curvature, fractures or dislocations within the bone.
This method makes use of curved planar reformation along a center-line defined by
the user. The selection of the VOI was performed in this reformatted µCT scan. To
prevent any measurement errors introduced by the reformation, the actual volume
measurements of the selected VOI are performed in the original scan volume. In
addition, we can visualize normalized cross-sections at an exact 90◦ angle or along
the longitudinal axis of bone, at any given point. This method allows side-by-side
visualizations of cross-sections and enables the comparison of diameter and volume




Female athymic mice (BALB/c nu/nu, 5 weeks old) mice were acquired from Charles
River (Charles River, L’Arbresle, France), housed in individually ventilated cages
while food and water were provided ad libitum. All surgical and analytical procedures
were performed under isoflurane gas anesthesia. At the end of the experimental
period, animals were sacrificed by cervical dislocation. Animal experiments were
approved by the local committee for animal health, ethics and research of Leiden
University Medical Center.
Cell lines & culture conditions
The MDA-231-B/Luc+ cell line (hereafter MDA-BO2), a bone-seeking and luciferase-
expressing subclone from the human breast cancer MDA-MB-231,7,8 was cultured
in DMEM (Invitrogen, Carlsbad, CA USA) containing 4.5 g glucose/l supplemented
with 10% fetal calf serum (FCS) (Lonza, Basel, Switzerland), 100 units/ml penicillin,
50 µg/ml streptomycin (Invitrogen) and 800 µg/ml geneticin/G418 (Invitrogen).
Cultures were maintained in a humidified incubator at 37◦C and 5% CO2.
Experimental setup
Intra-osseous inoculations with MDA-BO2 cells and sham operations; Mice received
an intra-osseous inoculation with MDA-BO2 cells (n = 8) into the right tibia as
described previously.8 After 42 days, mice were sacrificed by cervical dislocation and
the hind limbs were fixed overnight in 4% formaldehyde. Mice in the sham operated
group (partial bone marrow ablation) underwent the same procedure as the MDA-
BO2 inoculated animals except that the intra-osseous injection contained only PBS
and no tumor cells. After 10 and 42 days mice were sacrificed by cervical dislocation
(n = 5), the hind limbs were fixed.
Bisphosphonate treatment
Mice received daily sub-cutaneous injections with risedronic acid (150 µg/kg/day)
or a similar volume of PBS (n = 6). After 42 days mice were sacrificed by cervical
dislocation, the left hind limbs were fixed.
Radiograph and µCT analysis
After the experimental period, the hind limbs of all mice with a tumor were analyzed
by radiography (Kodak X-OMAT TL film, Eastman Kodak Company, Rochester, NY
USA) using a Faxitron 43805 X-ray system (Hewlett-Packard, Sunnyvale, CA USA).
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The radiographs were digitized and subsequently analyzed using Adobe Photoshop
CS3 V10.0.1 (Adobe Systems, San Jose, CA USA).
After the experimental period, µCT scans of the fixed hind limbs were made using
a SkyScan 1076 µCT scanner (SkyScan, Kontich, Belgium) using a source voltage
and current set to 40 kV and 250 µA, with a step size of 0.9◦ over a trajectory of 180◦.
Images were taken with an image pixel size of 9.03 µm and a frame averaging of 3 to
reduce noise. Reconstructions were made using nRecon V1.6.2.0 software (SkyScan)
with a beam hardening correction set to 20% and a ring artifact correction set to 5.
Processing, volume measurements and visualizations were performed using MeVisLab
V1.6 (MeVis Medical Solutions AG, Bremen, Germany). All µCT scans presented
here were made using an identical scanning protocol and reconstructed with identical
settings.
The method is very similar to the analysis of coronary arteries in CT angiography
images using multi-plane reformatting. First, a center-line through the bone was
defined. To do this, the user indicated manually the location of the center-line on
several slices throughout the original 3D data set (hereafter referred to as the original
space) after which a cubic B-spline was fitted through these points. Next, regular
spaced planes perpendicular to the center-line were extracted. These planes were
stacked into a new volume (hereafter referred to as the reformatted space). The user
defined a VOI by indicating a start and an end plane relative to anatomical features
in the reformatted space. These cut-off planes were transformed back into the original
space after which a region grower, initiated at a single or multiple seed point(s) was
used to select bone material. All connected voxels above a certain threshold value
were considered as bone. For the scans presented here, a lower threshold of 50 and an
upper threshold of 255 were used. Multiple seed points were needed in case there was
fractured bone. This threshold value was determined using the best separation value
from the intensity histogram and kept constant for all of the scans used within these
experiments. The region grower was set to stop when no further connected voxels
met the bone criterion or at the cut-off planes indicated by the user. This method
can be used for µCT datasets acquired using a different scanning protocol, scanner
or reconstruction parameters. In which case, threshold values would be required to
be optimized.
Results
All the reconstructed scans underwent a first visual assessment to check the quality
of the data sets. None of the scans contained obvious scanning artifacts which would
interfere with later analysis.
Center-line definition and generation of normalized cross-sections
The definition of a center-line is the pivotal first step of the analysis method. All fur-
ther steps and volume measurements are performed relative to this center-line. The
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center-line is calculated using several center points throughout the scan, indicated
manually by the user.
A center-line was successfully fitted through each of the scans. This center-line
was used to render cross-sections and longitudinal sections from the original space.
The orientation of the section planes was relative to the center-line, even though
the actual sections were generated from the original scan data (Figure 2.1). These
normalized cross-sections and longitudinal sections can be generated anywhere along
the center-line. Such normalized visualizations allow for side-by-side comparison
between multiple scans or between scans and histological sections.
Using a reformatted space to define a normalized volume of
interest
A reformatted space is used to define a VOI relative to the bone architecture in mul-
tiple scans, regardless of scan orientation or changes to the original bone anatomy.
The reformatted space was generated by straightening the center-line and reformat-
ting the rest of the scan around the new center-line accordingly. After selecting a
normalized VOI in this reformatted space, the VOI was mapped back to the original
scan space. This allowed the user to conduct measurements without distortion of the
data due to the reformatting steps.
To generate the reformatted space, regular spaced planes perpendicular to the
center-line were extracted from the original scan volume and stacked to form a new,
normalized, volume. In this new volume, the naturally curved bone was straightened
and orientated along the z-axis of the new stack regardless of its shape and position
in the original volume. Longitudinal sections of this reformatted bone could be
rendered and used for the assessment of the cortical thickness along the whole bone
(Figure 2.2a–c). In contrast to visualizations based on the original scan data, the
visualizations based on the reformatted data did not have artifacts resulting from
the angle between the bone and the sectioning plane.
The new reformatted space allowed the user to navigate through the scans and
locate positions relative to dominant anatomical features. For volume measurements,
the VOI was defined by two cut-off planes perpendicular to the bone. Throughout
these studies, the knee and the branch point between the tibia and fibula were used
as dominant anatomical features relative to which these cut-off planes were defined.
The cut-off planes were transformed back into the original space where the actual
volume was determined using a region grower with a threshold set for calcified tissue
(Figure 2.2d–e).
The center-line definition and generation of a reformatted space was tested on a
scan of a more complex pathological case. This was also to evaluate the performance
of the method in more extreme conditions. A scan of a fractured dislocated bone with
a callus was used to generate a complex dataset. A reformatted space was generated
and used to produce longitudinal cross-sections regardless of the fracture, dislocation
and callus (Figure 2.3).
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Figure 2.1: Fitting a spline and rendering cross-sections. (a) Semi transparent reconstruction of
the original scan volume with a global threshold set for bone. Several center points were
indicated manually and a spline has been fitted through these points. (b) Transversal cross-
sections can be generated perpendicular to the center-line at any point along the center-line.
Since the center-line follows the curvature of the bone, these cross-sections will always be
perpendicular, i.e. in a 90◦ angle, to the bone. These cross-sections can be used for ex-
act side-by-side comparison of the same section between different scans. (c) In a similar
fashion, osculating planes can be generated anywhere along the center-line resulting in lon-
gitudinal cross-sections of the original scan volume. The spline tangent vector at the point
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Figure 2.3: Generation of a reformatted space in a more severe pathological case. (a) Original
scan volume. (b) Volume rendering of the reformatted space. (c) Longitudinal cross-section
generated from the reformatted space. The reformatted space contains some artifacts due
to the planar reformation. These artifacts have no influence on the measured bone volume
since all actual measurements are performed within the original scan data.
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Volume measurements using normalized volumes of interest
Next, the variability between observations was assessed to demonstrate that the VOI
selection and volume measurement could be reproduced. In addition, we showed that
the volume measurements could be used to quantify biologically relevant changes in
bone volume.
To test the precision of the selection and quantification of a VOI, the center-
line definition and volume measurements of mouse tibiae were repeated ten times on
the same bone on ten different days performed by the same observer. The measured
bone volume was the tibial volume between the knee and the branch point of the tibia
and fibula, but not including the fibula (as shown in Figure 2.2e). The coefficient of
variation (cv) of these ten repeated measurements, defined as the ratio of the standard
deviation to the mean, was 0.001 indicating the low variation between observations.
To evaluate whether these volume measurements could be used to identify dif-
ferences in bone volume, the tibial bone volumes of the left tibiae of risedronic acid
treated mice were compared to that of untreated control mice of identical background,
sex and age. The tibia was selected by placing two cut-off planes in the reformat-
ted space, one through the knee and a second one at the branch point between the
tibia and fibula. The fibula was not included in the VOI. Bone volume increased by
approximately 22% (from 7.82mm3 ± 0.22 to 9.58mm3 ± 0.58) after treatment with
risedronic acid. The longitudinal cross-sections indicate the increase in trabecular
bone volume (Figure 2.4a).
Influence of intra-osseous inoculation on volume measurements
Intra-osseous inoculation of tumor cells is a method commonly used to study bone
metastasis of cancer.9 During the intra-osseous procedure the bone marrow is par-
tially flushed out of the bone. This partial bone marrow ablation has profound effects
on the local bone turnover. One week after ablation, the bone formation induced
from ablation of bone marrow reaches a maximum. After the first week, the bone
volumes had normalized over time as the bone recovered from the procedure.10,11
We evaluated the effects of intra-osseous inoculation procedure on volume measure-
ments of various VOIs to see how much it would interfere with the measurement of
tumor-induced volumetric changes.
Four different VOI definitions were used to gain an insight in the location of
volumetric changes; (1) the tibia from the branch point with the fibula up to the knee
(referred to as whole bone), (2) the distal half of the whole bone volume (referred to
as lower half), (3) the proximal half of the whole bone volume (referred to as upper
half) and (4) the proximal 25% of the whole bone volume (referred to as the upper
quarter).
The measurements were performed on a group of ten mice which received a sham
operation with PBS on the right tibiae following the protocol of intra-osseous injection
of cancer cells. The left tibiae were used as untreated controls. The mice were
sacrificed at 10 and 42 days after the procedure. The volume increase was defined
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Figure 2.4: Quantification of various volumes of interest. (a) Tibial volumes of saline treated
controls and risedronic acid treated animals after 42 days of treatment. The volumes of the
tibiae increased with approximately 22%, from 7.82mm3 ± 0.22 to 9.58mm3 ± 0.58. The
increase in trabecular bone volume can be appreciated form the detailed cross-sections of
the epiphysis. Error bars indicate SEM, ∗ : p < 0.05. (b) The effect of bone marrow ablation
on healthy animals. The graph shows the relative difference in bone volume between bones
after a partial bone marrow ablation (right hind limbs) compared to untreated control bones
(left hind limbs) 10 days and 42 days after the surgical procedure. The whole bone (WB),
lower half (LH) upper half (UH) and upper quarter (UQ) were measured in the same set
of scans for comparison. The effect of bone marrow ablation was less toward the proximal
end of the bone bath after 10 and 42 days. Error bars indicate SEM, ∗ : p < 0.05, ∗∗ : p <
0.01, ∗ ∗ ∗ : p < 0.001.
as a difference in percentage compared to the whole bone volume. The whole bone
volume increased approximately 19.5% (±2.1) within the first ten days after bone
marrow ablation. This relative volume increase was not the same for every region of
the bone. In the lower half, the volume increase was approximately 37.2% (±6.2) after
10 days, this was approximately 11.7% (±4.1) in the upper half and approximately
2.1% (±1.6) in the upper quarter. 42 days after partial bone marrow ablation, the
whole bone volume was still increased by approximately 16.2% (±0.5) and the lower
half volume was increased by approximately 40.9% (±3.4), the upper half volume by
approximately 8.0% (±2.2) and the upper quarter volume was completely normalized
after 42 days (Figure 2.4b). Following intra-osseous injection of cancer cells, a tumor
usually develops in the upper half of the bone.
Quantification of osteolysis induced volume changes
The relevance of volume measurements as a measure of cancer-induced osteolysis was
tested. In addition, improvement of data quality was observed when a smaller pre-

















































Figure 2.5: Quantification bone volume with and without osteolysis. (a) Bone volumes of the
upper half of the tibia of healthy control limbs (left hind limbs) and tumor bearing limbs
(right hind limbs) of the same animals, 42 days after tumor cell inoculations Error bars
indicate SEM, ∗∗ : p < 0.01. (b) Relative changes in bone volume between bones of healthy
control limbs (left hind limbs) and tumor bearing limbs (right hind limbs) of the same
animals, 42 days after tumor cell inoculations. The whole bone (WB) and upper half (UH)
were measured in the same scans for comparison. By measuring a smaller VOI, the relative
difference bone volume between the groups is enlarged. Both the WB and UH measurements
were significantly different from 0, but the p-value was smaller for the UH measurement
(p-values of 0.031 and 0.018 for the WB and UH measurement respectively). Error bars
indicate SEM, ∗ : p < 0.05.
the influence of the inoculation induced changes on volume measurements as well.
Mice received an intra-osseous inoculation of MDA-BO2 cells, an osteolytic breast
cancer cell line. The mice were sacrificed after 42 days, this is comparable to other
experiments performed using this specific MDA subclone.12–14 µCT scans were made
of both hind limbs, with and without a tumor.
The volumes of the upper half of the tibiae were used to quantify the loss of bone
volume in the diseased limbs compared to the healthy limbs (Figure 2.5a). The choice
for measuring the upper half of the tibiae was based on the differential effects of the
intra-osseous inoculation method on bone volume as described in Figure 2.4b and
the localization of tumor growth after the inoculation procedure. The bone volume
of the upper half decreased significantly compared to the same volume in the healthy
bone.
Volume measurements of the whole bone and the upper half were compared to
evaluate whether the selection of a smaller VOI improved data quality. Whole bone
and upper half volume measurements were performed on the same µCT data sets to
show the effect of selecting a smaller VOI and its impact on the decrease in bone
volume. The osteolysis-induced bone loss was calculated as a percentage decrease in
bone volume of the pathologic bone compared to the healthy bone. The volume of
the whole osteolytic bones decreased by approximately 47% compared to the healthy
control bones. This volume decrease was approximately 59% when measured in the
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Figure 2.6: Radiography measurements are dependent on the projection. (a) Radiographs of
two bones. The osteolytic lesion surface of bone #1 was 3420 pixels, the osteolytic lesion
surface of bone #2 was 3402 pixels. (b) µCT scans of the same to bones as in (a). It can be
concluded from the µCT scans by visual assessment that the osteolytic lesion in bone #1 is
smaller than the osteolytic lesion in bone #2. Quantification of the upper half bone volume
confirms this observation, the upper half volumes of bones #1 and #2 are 6.5mm3 and
3.9mm3, respectively. This example is illustrative for how the flattening of a 3D structure
can result in incorrect observations.
upper half of the tibiae. In both cases the standard error of the mean was 15 (Figure
2.5b). These results indicate that volume differences can be magnified by selection
of a smaller VOI, thereby improving the sensitivity of volume measurements as a
method to quantify osteolysis.
Finally, radiographs of the osteolytic bones were made to show how the flattening
of a 3D structure can influence measurements of osteolysis. To illustrate this problem,
two bones with a comparable osteolytic surface on radiographs were selected for
µCT analysis. The volumetric analysis of the µCT scans of these bones revealed
that the osteolytic lesion of one bone was more severe than the other (Figure 2.6).
The radiographs were acquired on one film simultaneously and processed identically.
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Discussion
A new method to select VOIs and quantify bone volumes in a normalized way is
presented in this study. Drugs and diseases can induce major structural changes
in bone. Traditional quantification methods often use the growth plate as primary
landmark which is often destroyed in cases of severe osteolysis. The current method
reduces the dependency on this structure by using the knee and the branch point
of tibia and fibula, two structures which are very unlikely to disappear. Moreover,
performing the VOI selection relative to a centerline makes it possible to compensate
for large structural deformations such as fractures and dislocations. Since all bone
segments are presented in a normalized way, the user can indicate identical start and
end planes to define a VOI in different scans. In addition, the use of a center-line
enables the user to generate normalized sections that can be used to compare between
scans or to compare scans with histological sections. The actual measurement of the
selected volume is performed in the original scan to prevent measurement errors due
to compression and/or expansion and errors in surface voxel definition that occur
during reformation of a scan.
Osteolysis is currently quantified using radiography analysis. However, µCT scans
are rarely used for quantification and instead they are used for visual representation
as supportive data. One of the reasons for this is the lack of reliable methods for
normalized processing of µCT scans. However, volume measurements can provide
a valuable addition, not only for the quantification of osteolytic lesions, but for
osteoblastic lesions as well. 2D radiographs are able to show the shadow projection
of a bone with a specific 3D structure. The projection and flattening of a 3D structure
can result in lesions projected on top of each other or along the side of the bone.
However, the problem is that measurement errors are inadvertently introduced as
shown in Figure 2.6. Moreover, volume measurements are not prone to observer bias
when using detailed predefined definitions of a VOI relative to the bone.
Volume measurements can be used to quantify changes in bone volume of both
osteolytic and osteoblastic lesions. This in contrast to 2D modalities which cannot
be used to quantify subtle increases in bone volume. However, interpretation of the
data becomes more complex in cases where both osteolytic and osteoblastic processes
occur in the same bone. For instance, procedures commonly used to inoculate bones
with cancer cells can induce changes in bone volume (Figure 2.4). As a result,
measurements of the entire tibial volume can be misleading. We showed that the
increase in bone volume mainly occurs in the lower half of the tibia. Thus, the
effects of bone marrow ablation on the volume measurements can be minimized by
limiting the VOI to the upper half of the tibia, which is the actual area of the bone
where a tumor grows. This is an example of how careful selection of a VOI is crucial
to generate reliable data.
Recent advances have been made in using µCT scans for the quantitative as-
sessment of osteolysis. Johnson et al. followed bone loss over time in µCT scans
made at multiple time points. The authors elegantly showed that there is no effect
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of repeated X-ray exposure on tumor growth following their µCT scanning protocol.
Using the entire bone volumes, they were able to visually detect osteolytic lesions one
week after tumor cell inoculation and statistically differentiated lesions at week three
more effectively than radiography.15 It is feasible that the results from their study
could be further improved by selection of a smaller VOI. As we have shown from
our own study, the work of Johnson et al. could have also benefited from use of a
smaller VOI. This could have eliminated the disruption of the volume measurements
by other processes such as the direct effect of intra-osseous inoculations.
The relative change in bone volume is increased when measuring a smaller VOI,
this while the standard error of the mean remains the same (Figure 2.5). Opti-
mization of the measured VOI increases the sensitivity of volume measurements for
detecting differences between osteolytic or osteoblastic lesion sizes. Observer bias is
still minimal as the VOI is pre defined as a volume relative to the anatomy of the
bone.
Other methods used to analyze smaller VOIs in µCT scans, which use a sub-
volume instead of the entire bone volume, make use of a VOI with predefined dimen-
sions. This VOI is ‘a box’ which is placed around a part of the scan. As a result, the
selected VOI strongly depends on the scan orientation. Moreover, the curved shape
of the tibia and possible fractures make it impossible to have two planes in a z-axis
where both would cut the bone in a 90◦ angle. We eliminated these problems by
using a VOI which is relative to the anatomy of the bone.
The reliable and reproducible selection of a VOI is pivotal when performing vol-
ume measurements in order to quantify the effects of osteolytic or osteoblastic effects.
Here, we presented a curved planar reformation based approach to generate various
normalized cross-sections. By using a reformatted space to select a VOI relative to
the anatomy, we were able to eliminate measurement errors due to the orientation
of the scan and deformations of the bone (e.g. dislocations, fractures). The effect of
other processes elsewhere in the bone is eliminated by selecting a small VOI around
the lesion. In conclusion, we found that by selecting a smaller VOI, the relative
changes in bone volume are magnified which increases the sensitivity of our method
of analysis as compared to other approaches.
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Abstract
Purpose Quantification of osteolysis is crucial for monitoring treatment effects in
preclinical research and should be based on µCT data rather than conventional two
dimensional radiographs to obtain optimal accuracy. However, data assessment is
greatly complicated in the case of three dimensional data. This paper presents an
automated method to follow osteolytic lesions quantitatively and visually over time
in whole-body µCT data of mice.
Procedures This novel approach is based on a previously published approach to
coarsely locate user-defined structures of interest in the data and present them in
a standardized manner (Baiker et al., Med Image Anal 14:723–737, 2010; Kok et
al., IEEE Trand Vis Comput Graph 16:1396–1404, 2010). Here, we extend this
framework by presenting a highly accurate way to automatically measure the volumes
of individual bones and demonstrate the technique by following the effect of osteolysis
in the tibia of a mouse over time. Besides presenting quantitative results, we also
give a visualization of the measured volume to be able to investigate the performance
of the method qualitatively. In addition, we describe an approach to measure and
visualize cortical bone thickness, which allows assessing local effects of osteolysis and
bone remodeling. The presented techniques are fully automated and therefore allow
obtaining objective results, which are independent of human observer performance
variations. In addition, the time typically required to analyze whole-body data is
greatly reduced.
Results Evaluation of the approaches was performed using µCT follow-up datasets
of 15 mice (n = 15), with induced bone metastases in the right tibia. All animals were
scanned three times: at baseline, after 3 and 7 weeks. For each dataset, our method
was used to locate the tibia and measure the bone volume. To assess the performance
of the automated method, bone volume measurements were also done by two human
experts. A quantitative comparison of the results of the automated method with
the human observers showed that there is a high correlation between the observers
(r = 0.9996), between the first observer and the presented method (r = 0.9939),
and also between the second observer and the presented method (r = 0.9937). In
addition, Bland-Altman plots revealed excellent agreement between the observers
and the automated method (inter-observer bone volume variability, 0.59 ± 0.64%;
Obs1 vs. Auto, 0.26±2.53% and Obs2 vs. Auto, −0.33±2.61%). Statistical analysis
yielded no significant difference (p = 0.10) between the manual and the automated
bone measurements and thus the method yields optimum results. This could also be
confirmed visually, based on the graphical representations of the bone volumes. The
performance of the bone thickness measurements was assessed qualitatively.
Conclusions We come to the conclusion that the presented method allows to mea-
sure and visualize local bone volume and thickness in longitudinal data in an accurate
and robust manner, proving that the automated tool is a fast and user friendly al-
ternative to manual analysis.
Automated VOI Selection and Volume Measurements 43
Introduction
Breast cancer metastasizes preferentially to bone. Post mortem evaluation revealed
that 70% of patients who died of breast cancer had bone metastases present in the
skeleton.1 Bone metastases cause severe morbidity in living patients such as bone
pain, fracture, hypercalcemia, and nerve compression.2,3 As a result, quantification
of osteolytic lesion size is pivotal in preclinical research of metastatic bone disease and
treatment evaluation in small animal models. Osteolysis is currently quantified using
two dimensional (2D) radiographs.4,5 The scoring of these radiographs is performed
manually by drawing a region of interest (ROI) around the lesion and measuring
the bone area. The problem with this procedure is that lesions may be projected
on top of each other and will therefore be underestimated when quantified, due to
the flattening of the three dimensional (3D) structure.6 The same may happen for
lesions on the side of bone. Furthermore, performing the analysis manually is prone to
observer bias. µCT datasets provide spatial information, suitable for measurements
of various bone parameters such as bone volume, bone thickness, and bone mineral
density. These measurements are potentially more informative than the radiographic
analyses. Also, µCT enables the researcher to study the overall bone structure.
The use of µCT for quantitative measurements is not without difficulties. The
shape and position of a volume of interest (VOI, the 3D counterpart of a ROI in
2D) in a 3D dataset greatly influence the measurement results. Therefore, it is
crucial that the selection of a VOI is reproducible and not affected by the scan
orientation or the observer who performs the procedure. We previously published
a manual approach for the normalized selection of a region of interest in complex
shapes (Chapter 2).6 This manual approach provides good and reproducible results
but is very time-consuming and requires well trained observers.
The comparison of whole-body datasets from longitudinal studies is even more
difficult. Variation in posture of the animal during scans taken at different scan dates
makes it nearly impossible to spot subtle disease induced differences between scans.7
We previously published an approach to automatically align the skeletons of an-
imals that were scanned at different points in time. The method can handle large
postural differences between animals and as a result, specifically designed holders
that are sometimes used to coarsely align animals8 are not required. In addition,
the user can select individual bones and generate side-by-side visualizations of these
bones from multiple longitudinal datasets (Figure 3.1). Such normalized visual-
izations greatly facilitate detailed qualitative assessment of structures in multiple
complex and large datasets.9
Here we describe an addition to this method, which enables the user to perform
automated quantitative measurements of bone volume and thickness alongside the
visual output. For evaluation, we applied the method to segment the femur and
the tibia / fibula in whole-body follow-up µCT datasets and measured the bone vol-
ume and cortical thickness at three points in time: baseline, 3 and 7 weeks. To test
whether this approach could be used to quantify biologically relevant changes in bone
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Figure 3.1: An overview of our previously published approach to coarsely locate user-defined
structures of interest in follow-up whole-body data7 and present them in a stan-
dardized manner.9 (a) The skeleton of an atlas is registered (aligned) to µCT data ac-
quired at N time points T0 . . . TN . (b) An example of the registration result for one dataset.
(c) Based on the registration result, we can determine volumes of interest (VOIs) around
individual bones. The VOIs are shown as yellow boxes. (d) Based on the VOIs, the data
can be put in a standardized layout using Articulated Planar Reformation (APR).9 (e) The
advantage of the standardized layout is, is that the same structures in datasets from different
time points (T0 . . . TN) can be visualized side-by-side, greatly facilitating data comparison.
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volume, breast cancer cells were injected into the right tibia after the baseline scan.
The left tibia remained untreated and served as a reference. The results of the auto-
mated measurements are compared with manual measurements of two experts. We
show that the automated segmentation and volume measurements perform equally
accurate and reproducible as manual segmentation and volume measurements.
In summary, the goals of this work are to:
• Automate the task of measuring the volume of a user-defined bone in whole-
body in vivo µCT data and demonstrate the method by measuring the bone
volume of the proximal tibia / fibula at several points in time
• Compare the automated measurements with two human observers and show
that the results are not significantly different
• Present a way to assess the measurement quality visually, by providing proper
visualization
• Present a method to assess effects of osteolysis and bone remodeling locally




Fifteen (n = 15) female nude mice (BALB/c nu/nu, 6 weeks old) were acquired from
Charles River (Charles River, L’Arbresle, France), housed in individually ventilated
cages, food and water were provided ad libitum. Surgical procedures and µCT imag-
ing were performed under injection anesthesia (100mg/kg ketamine + 12.5mg/kg
xylazine). Animals were sacrificed by cervical dislocation at the end of the experi-
mental period. Animal experiments were approved by the local committee for animal
health, ethics and research of Leiden University Medical Center.
Cell lines & culture conditions
The cell line MDA-231-B/Luc+ (hereafter MDA-BO2), a bone-seeking and luciferase-
expressing subclone from the human breast cancer MDA-MB-231,10,11 was cultured
in DMEM (Invitrogen, Carlsbad, CA, USA) containing 4.5g glucose/l supplemented
with 10% fetal calf serum (FCS) (Lonza, Basel, Switzerland), 100 units/ml penicillin,
50µg/ml streptomycin (Invitrogen), and 800µg/ml geneticin/G418 (Invitrogen). The
cells were monthly checked for mycoplasma infection by PCR. The cells were donated
by G. van der Pluijm (Leiden University Medical Center, Leiden, The Netherlands).
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Experimental setup
MDA-BO2 cells were injected into the right tibiae as described previously.11 In brief,
two holes were drilled through the bone cortex of the right tibia with a 25-gauge
needle (25G 5/8, BD MicroFine, Becton Dickinson, Franklin Lakes, NJ, USA) and
bone marrow was flushed out. Subsequently, 250,000 MDA-BO2 cells per 10 µl PBS
were injected into the right tibiae of the animals. µCT scans were made before the
tumor cell inoculation (T0) in supine position, 3 weeks after tumor cell inoculation
(T1) in prone position, and 7 weeks after tumor cell inoculation (T2) in supine
position. The animals were scanned with arbitrary limb position.
µCT data acquisition
µCT scans were made using a SkyScan 1076 µCT scanner (SkyScan, Kontich, Bel-
gium) using a source voltage and current set to 50kV and 200µA, respectively, with
an X-ray source rotation step size of 1.5◦ over a trajectory of 180◦. Reconstructions
were made using the nRecon V1.6.2.0 software (SkyScan) with a beam hardening
correction set to 10%, a ring artifact correction set to 10, and the dynamic range set
to −1, 000− 4, 000 Hounsfield units. The datasets were reconstructed with voxel size
36.5 × 36.5 × 36.5µm3. Neither cardiac nor respiratory gating was used.
Manual segmentation of the tibia / fibula
To assess the performance of the automated tibia volume measurements, two field
experts were asked to segment the proximal part of the right tibia. To be able to
use the data at full resolution, this was not based on the whole-body dataset but on
a sub-volume, corresponding to the right tibia, which was automatically determined
following the procedure in Figure 3.1. An example of such a sub-volume is shown
in Figure 3.2. Starting with this sub-volume, the experts were asked to segment the
proximal part of the tibia / fibula, i.e., the part between the knee and the location
where tibia and fibula separate. The manual segmentation was performed using a
tool that was developed in-house with MeVisLab V1.6 (MeVis Medical Solutions AG,
Bremen, Germany) as described in Chapter 2.6
After segmentation, the number of bone voxels was determined using a threshold
value to separate bone from background. To determine the optimum threshold for
the in vivo datasets, the tibia of one of the animals was scanned ex vivo with high
resolution (9.125 × 9.125 × 9.125µm3) after the follow-up experiment. Subsequently,
the tibial bone volume was measured. To find the optimum threshold, for segmen-
tation of bone from the background in the low-resolution data, the threshold was
set such that the volume of the tibia of the same mouse in the low resolution data
was the same as the volume of the tibia in the high resolution data. This thresh-
old was kept constant for segmentation of all datasets. The result was a volume
dataset with the same size as the initial sub-volume with voxels labeled as relevant
bone, i.e., the proximal tibia / fibula, and background (including irrelevant bone).
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Figure 3.2: Example of an automatically determined sub-volume, including the right tibia.
The bone surface is shown together with the corresponding sub-volume.
Therefore, the bone volume of the proximal tibia / fibula could be determined by
multiplying the total amount of bone voxels with the voxel volume, i.e., in our case
amount of voxels × (36.5 × 36.5 × 36.5)µm3. To be able to assess the quality of
the segmentation visually, we provided a surface representation of the manually seg-
mented sub-volume. The tibia / fibula bone volume served as the reference for the
automated method presented in the next subchapter.
Automated segmentation of the tibia / fibula
An automated method should yield results that are as similar as possible to the re-
sults a human observer would obtain. Therefore, it should be designed such that it
mimics the manual procedure as much as possible. Just as for the manual segmenta-
tion, presented in the previous subchapter, the automated segmentation was based
on a sub-volume as shown in Figure 3.2 and the goal was to segment the proximal
part of the tibia / fibula. First, a center-line was determined that runs through the
center of the femur, the knee and the center of the tibia, based on the registration of
the skeleton atlas to the µCT data. To this end, we defined 21 bone center locations
(10 in the femur, 11 in the tibia) in the atlas. Subsequently, if the atlas bones are
registered to the data (Figure 3.1b), these atlas bone center locations are approxi-
mately in the bone centers of the femur and the tibia in the µCT data (the bone
center locations do only have to be defined once for the atlas). Subsequently, a bone
center-line was derived using cubic B-spline fitting through the bone centers. Next,
the volume was segmented into bone and background using global thresholding with
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Figure 3.3: Demonstration of how the bone thickness D is determined automatically if osteo-
lytic lesions are present. The slices from the µCT sub-volume that are orthogonal to
the center-line, with an overlay of the voxels labeled “bone” (blue net), are shown. Along
the bone center-line (orange stars), grey-value profiles are taken in axial direction at evenly
spaced locations along the center-line. The location close to the knee (left) and the locations
halfway between the knee and the tibia / fibula separation (middle) and close to the tibia
/ fibula separation (right) are shown. Points on the inner boundaries are indicated by red
stars, corresponding points on the outer boundaries by green stars. The black arrows indicate
the directions, along which the grey value profiles for the bone thickness measurement are
derived. An example of a profile path is shown in red (middle). The inset shows an example
of a grey-value profile in blue and its gradient values in green (dx symbolizes a mathematical
derivation). The bone boundaries can be found where the gradients are maximum (red stars
in the inset) and the bone thickness D is the distance between the boundaries.
the same threshold as was used for the manual segmentation (see previous subsec-
tion). Following the bone center-line from the knee towards the distal part of the
tibia, the separation of the tibia and the fibula was determined using a hierarchi-
cal clustering technique with single linkage12 that determined the number of bone
clusters at regular spaced locations along the center-line. The Euclidean distance
between points was chosen as the dissimilarity measure. The transition from two
clusters (tibia and fibula) to one cluster identified the location of bone separation.
Figure 3.3 (right) shows a slice, perpendicular to the center-line, which is close to
this point (tibia = large spot, fibula = small spot).
Separation of the tibia / fibula from the femur was done in a slightly different
way as compared with the manual procedure because it is very difficult to automat-
ically determine a flat separation plane within the knee. Therefore, we chose to rely
on a classifier that automatically separates all voxels labeled as “bone” (i.e., after
thresholding) into the two classes “femur” and “tibia / fibula”. The classifier was
trained using volumetric (tetrahedral) meshes of the femur and tibia atlas after reg-
istration (Figure 3.1b). Each node location of the meshes was weighted with a 3D
Gaussian probability density function with width h (Parzen kernel density estima-
tion12). Subsequently, all individual probability densities were summed up, yielding
a bone-dependent posterior probability density value within the entire data volume.
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A voxel labeled as “bone” can thus be identified as “femur” or “tibia / fibula”, de-
pending on its location in the volume, depending on which of the two classes has the
highest posterior probability at that location. The parameter h was optimized using
a leave-one-out test, based on the available datasets. Finally, the bone volume of
the proximal tibia / fibula could be derived by counting the bone voxels classified as
“tibia / fibula” along the center-line, up to the tibia / fibula separation determined
before and multiplying the total amount of bone voxels with the voxel volume. To
assess the quality of the automated segmentation visually, we provided a surface
representation of the result.
Automated segmentation of the femur
As a proof of concept that the automated segmentation method can be applied to
other skeletal elements besides the tibia as well, we demonstrate an automated seg-
mentation of the femur. The femur is connected proximally to the pelvis and distally
to the tibia. Following the procedure given in the “Automated Segmentation of the
tibia / fibula” section, the tibia was separated from the femur in a first step. Second,
volumetric meshes of the atlas femur and the atlas pelvis after skeleton registration
were used to derive a 3D posterior probability density function for these bones and
to determine the separation of pelvis and femur, following the same procedure as
described in the “Automated Segmentation of the tibia / fibula” section. The kernel
width h was identical to the one used for the separation of the tibia and the femur.
To assess the reproducibility of the volume measurements, the volume of the left
femur of three animals was measured at all points in time and compared with the
volume of the right femur over time. In addition, the bones were segmented manually
to assess measurement accuracy. To ensure that the influence of the induced cancer
cells had a minimal effect on the femur bone volume, we chose three animals where
osteolysis had only slightly progressed over time.
Automated bone thickness measurements and visualization
Accurate knowledge of local bone thickness enables to follow the progress of osteolysis
and bone remodeling over time. Therefore, a method is required to measure bone
thickness in 3D and to relate the measurement to the exact location on the bone.
Above that, the method should be able to handle severe structural changes over time,
induced by osteolysis.
There are mainly two approaches described in the literature to assess bone thick-
ness in volumetric data: volume-based methods and surface (feature)-based meth-
ods.13 These are focusing mainly on measuring trabecular bone and the approaches
generally take the entire image domain into account. The advantage is that struc-
tures with very different shape can be analyzed. Although the approaches could be
used for measuring cortical bone as well, the tube-like shape of long-bones enables
another approach. Since the registration of the skeleton atlas to the data yields a
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coarse segmentation of the skeleton, we can map a bone center-line, defined in the
atlas femur and tibia, to the femur and tibia in the data. Subsequently, we can
employ a technique similar to that presented in Van der Geest et al.,14 where the
authors measure the diameter and wall thickness of blood vessels in magnetic reso-
nance angiography and computed tomography angiography, based on slices that are
orthogonal to the vessel center-line. The great advantage of relying on a center-line
is that it is possible to determine exactly at which locations along the center-line the
thickness should be measured. The main difference between analyzing vessels and
potentially osteolytic bone is that vessels are continuous structures while bone can
be highly fractured and contain holes.
The methods for trabecular thickness measurement generally take the entire im-
age domain into account, which can be very time-consuming especially for large
volumes or surfaces with a great amount of vertices. The proposed approach enables
to greatly reduce computational burden. Above that, being able to define the thick-
ness measurement based on a center-line allows to sample certain areas more densely
than others, yielding more accurate measurements.
To determine the cortical bone thickness of the tibia automatically, we relied on
the bone center-line presented in the previous section and the sub-volume according to
Figure 3.2. At regularly spaced locations, following the center-line in distal direction,
grey-value profiles were extracted in axial direction, starting from the center-line and
progressing outwards. In total, 360 profiles were taken per location, with 1◦ angle
difference between them, thus covering an entire circle, oriented orthogonal to the
center-line. Since the center-line lies in an area with low intensity (bone marrow), the
grey-value profile will consist of low values at the beginning, high values, when the
bone is crossed and again low values outside the bone (muscle tissue). An example
of such a profile is given in Figure 3.3 (middle). Subsequently, the inner boundary of
the bone can be determined, using the highest positive gradient of the profile. Doing
this for all 360 profiles yielded 360 points that are located at the inner boundary of
the bone. However, since the center-line may not always lie exactly in the center
these points are usually not evenly distributed along the boundary. Therefore, we
applied an additional resampling step so that the points had a minimum distance
of one voxel. Examples of resulting inner boundaries are shown in Figure 3.3 (red
stars). Next, again grey-value profiles were taken, but this time orthogonal to the
inner boundary of the bone, starting inside the bone and progressing outwards. An
example path of such a profile is shown as a red line in Figure 3.3 (middle). Finally,
the bone thickness D could be determined using the highest positive and the highest
negative gradient of the profile, demarcating the inner and the outer boundary of the
bone. This is demonstrated in the inset in Figure 3.3 (middle). Hence, our definition
of bone thickness is the distance from the inner boundary to the outer boundary of
the cortex, orthogonal to the inner boundary.
The bone thickness measurements can be uniquely related to the location on the
bone, where they were derived. To be able to assess the bone thickness locally and
still have the anatomical context information available, we present a visualization
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that is based on a surface representation of all bone in the sub-volume (Figure 3.2).
To each location on the bone surface, we linked the corresponding bone thickness
and assigned a value-dependent color. The result is a surface representation of the
bone, on which the color indicates the bone thickness.
The automated segmentations and bone thickness measurements and visualiza-
tions were performed using Matlab 2010b (The Mathworks, Natick, USA).
Quantitative analysis of measurement results
To assess how similar the results of the automated method and the human experts
are, Bland-Altman15 plots as well as Pearson’s correlation coefficients are presented.
To investigate in detail the influence of the time point (i.e., baseline, first, and second
follow-up), the bone (i.e., healthy and pathologic), and the observer (i.e., automated,
observer 1, and observer 2) on the bone volume measurement, we performed a statis-
tical analysis using a three-way repeated measures analysis of variance (ANOVA),16
with the bone volume as the dependent variable and observers, bone (i.e., healthy
and pathologic), and time point as the independent variables (3 × 2 × 3 levels). A
repeated measure design requires the variances of the differences between levels to
be equal. Therefore, Mauchly’s sphericity test should be non-significant if we are
to assume that the condition of sphericity has been met. If the results of the test
indicated that the assumption of sphericity was violated, the degrees of freedom were
corrected using Greenhouse-Geisser estimates of sphericity.16 To identify significant
differences between group means for main and interaction effects, a Tukey honest
significant difference (HSD) post hoc test was used. Effects were considered to be
significant if p < 0.05. The statistical analysis was performed using Statistica 8.0
(StatSoft, Tulsa, USA).
Results
To be able to assess the accuracy of a manual and an automated segmentation of the
proximal tibia / fibula, surface visualizations are generated after the measurements.
Examples are shown in Figure 3.4.
The results of the correlation tests are shown in the top row of Figure 3.5 and the
measurement agreements are presented in the bottom row of Figure 3.5. To assess
possible influence of the time point on the agreement, the data are shown for each
time point individually (see legends).
Mauchly’s test indicated a violation of the sphericity assumption and therefore
degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity
(see Table 3.1). The results show that there are significant differences in measured
bone volume for the main effect Time, F (1.39, 16.73) = 28.80 (p < 0.001), as well
as the interaction effects Method × Time, F (1.63, 19.59) = 16.71, (p < 0.001), and
Bone × Time, F (1.08, 12.93) = 12.75 (p < 0.05). The Tukey HSD post hoc tests
revealed a significant difference in bone volume between T0 and T1 (p < 0.001) as
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Figure 3.4: Manual and automated segmentation. Bone surface visualization after manual seg-
mentation of the proximal tibia / fibula (left). Bone surface visualization after automated
segmentation of the proximal tibia / fibula (right; blue femur, red proximal tibia / fibula,
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T1: 0.07 ± 0.06
T2: 0.08 ± 0.07
T1: 0.06 ± 0.19
T2: −0.10 ± 0.22
T0:   0.10 ± 0.17   
T1: −0.01 ± 0.18
T2: −0.18 ± 0.21
Figure 3.5: Correlation and agreement between human observers and the automated method.
Correlation between the measurements (in mm3) of the two human observers and the au-
tomated method (top row). Obs1 vs. Obs2, Auto vs. Obs2 and Auto vs. Obs1 are shown.
The blue line represents a linear best fit, defined by the function in the legend. The Pearson
correlation r, based on the data (red), is also shown in the legend. Bland-Altman plots rep-
resenting the measurement agreement between the two human observers and the automated
method (bottom row). The black lines indicate the grand means (line) ± 1.96 times the
standard deviation (broken line), which are 0.06 ± 0.12, 0.03 ± 0.43 and −0.03 ± 0.44mm3,
respectively. The arrows indicate the measurement with maximum disagreement between
the observers. To assess, if the agreement is dependent on the time point when the data was
acquired, these are shown in different colors (red circles baseline or T0, black diamonds T1,
blue stars T2). Note that the values in the legends are the means ±1 times the standard
deviation.
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well as T0 and T2 (p < 0.001). There was no significant difference between T1 and
T2 (p > 0.05).
For the Bone × Time interaction effect (Figure 3.6, top left), relevant significant
effects were present for healthy vs. pathologic bone at T2 (p < 0.001), but not at
T0 and T1 (both p > 0.05). For the Method × Time interaction effect (Figure
3.6, top right), relevant significant effects were present for Obs1 vs. Auto and Obs2
vs. Auto at T0 (p < 0.05 and p < 0.001) but not for Obs1 vs. Obs2 at T0 (p > 0.05).
Furthermore there were significant effects for Obs1 vs. Auto and Obs2 vs. Auto at
T2 (p < 0.001 and p < 0.05) but not for Obs1 vs. Obs2 at T2 (p > 0.05). There were
no significant effects at T1.
The results of the comparison of the difference in bone volume between healthy
and pathologic bone for six different mice are given in Figure 3.6 (middle and bottom
rows).
The results of the femur segmentation and subsequent volume measurements
are shown in Figure 3.7. The average volume of the right and the left femur was
0.89 ± 0.64% when measured manually and 0.83 ± 0.53% when measured automati-
cally. To see if there is a significant difference between the human observer and the
automated method, a similar statistical analysis as presented in the “Quantitative
Analysis of Measurement Results” section was performed, this time including one hu-
man observer instead of two. Mauchly’s test indicated no violation of the sphericity
assumption (p > 0.05). The results show that the main effect method is significant
F (1, 2) = 92.894, p < 0.05, and the mean difference between the automated and the
manual method is 2.15 ± 0.75%. This means that the automated method results in
lower measured volumes than the manual method.
A comparison of the development of the bone thickness over time for a healthy
and a pathologic bone are given in Figure 4.4 by means of bone surface visualizations,
where color indicates the bone thickness.
Discussion
In this article, we described a fully automated approach to analyze skeletal changes
in rodent whole-body µCT scans. The automated approach is capable to (1) align
scans of the same animal, taken at different time points; (2) automatically segment a
sub-volume (VOI) in these scans; (3) measure the bone volume; (4) measure cortical
thickness; and (5) visualize it by means of assigning thickness-dependent colors. In
addition, the user can visually check the segmentation performance using 3D bone
surface representations and can generate normalized sections of identical sectioning
planes in longitudinal scans for side-by-side comparison.
Conventional analysis of radiographs involves identifying osteolytic lesions man-
ually. The procedure of manually drawing a region of interest is prone to observer
bias and small changes in thickness or multiple lesions projected on top of each other
are easily overlooked.6 Manual analysis of µCT data is a better alternative, but is
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Figure 3.6: Mean volumes of the tibia. Mean bone volume (mm3) over time for the pathologic
(Path) and the healthy (Heal) bones, respectively (top row), Bone × Time interaction (left)
and bone volume over time for the two human observers (Obs1, Obs2) and the automated
method (Auto), Observer × Time interaction (right). The results are based on including
all mice. Error bars indicate 95% confidence intervals. Mean bone volume (mm3) and the
standard deviation of the healthy (Heal) and pathologic (Path) bones for six different mice
(a–f) over time, averaging the measurements of the automated method and the two human































Figure 3.7: Volume measurements of the femur. Result of the automated (Auto) and manual (Obs1)
volume measurement for the right (ri) and left (le) femur for three different mice (a–c) over
time.
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Figure 3.8: Bone thickness maps. Comparison of the bone thickness development over time for a
healthy and a pathologic bone. Bone surface representations are shown. The colors indicate
the bone thickness at each location on the bone. The bone marrow was partially flushed
out of the bone during the intra-osseous inoculation used to induce bone metastases. This
partial bone marrow ablation leads to a local increase in bone volume preceding cancer-
induced osteolysis.6 The arrow indicates this local increase in bone thickness around the
site of early osteolysis. Note that the measurements at the distal end of the femur and the
proximal end of the tibia are not meaningful because at these locations, a substantial amount
of trabecular bone is present. However, bone thickness measurements are only meaningful
for cortical bone.
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An automated method for µCT analysis has several advantages over manual anal-
ysis. The risk of non-objectivity and inter-observer variability is greatly reduced by
minimizing the active manual input of the researcher. Only an automated approach
can be purely objective and handle every dataset in exactly the same manner. Addi-
tionally, an automated analysis method is much faster than any manual procedure.
Thus, by automating the analysis, a relatively larger number of scans can be evalu-
ated, compared to a human observer
Researchers want to know exactly how quantified data is generated and tend to
dislike automated black-box approaches. To enable the researcher to check every
step along the way, the automated method generates visualizations of the segmented
volume. These visualizations can be evaluated after the analysis is complete. The
automatic segmentation can be overruled manually or some datasets can be excluded
from further analysis. Moreover, the cortical thickness maps enable the researcher to
directly pinpoint where structural changes of the cortical bone occurred. This way,
the cortical thickness maps help identify areas of interest in the original scan data
and in other modalities such as histological sections. The assessment of trabecular
bone is not possible with the proposed method because the relatively low resolution
of the in vivo data (36.5×36.5×36.5µm3) renders measuring the trabecular thickness
accurately very difficult.17
We validated the presented automated method by comparing it to the “best avail-
able” method, namely manual bone segmentation and bone volume measurements.
Therefore, we acquired datasets of 15 mice (n = 15) with induced bone metastases
in the tibia at three points in time. The volume measurement results show that
there is an excellent correlation between the human observers and the automated
method: rObs1Obs2 = 0.9996, rAutoObs2 = 0.9939, and rAutoObs1 = 0.9937. The
Bland-Altman plots (Figure 3.5, bottom row) based on all data indicate excellent
agreement among the two human observers (inter-observer variability) as well as the
observers and the automated method. There is no obvious relation between the dif-
ference and the mean. Residual disagreement can therefore be explained by the bias
and the deviation, which is very low in all cases, namely 0.59± 0.64%, 0.26± 2.53%,
and −0.33 ± 2.61%, respectively. The residual errors are the result of mainly two
factors that may influence the measurement outcome: the registration accuracy, and
subsequently the segmentation accuracy, and the chosen threshold to separate bone
from the background. The registration accuracy has the largest influence on the
result and therefore, improving the accuracy would require a modification of the reg-
istration method. Special attention should be paid to the robustness of potential
methods with respect to bone resorption. The thresholding procedure also influences
the measured volume because both values are inversely related, i.e., if the threshold
value increases, the volume decreases and vice versa. We chose a global threshold
since the resolution of the in vivo data does not allow reliable segmentation of the
trabecular bone17 but methods including local thresholds may be more accurate, if
data resolution increases.
Ideally, the automated measurements are identical to the manual measurements.
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The ANOVA revealed no significant difference between observers (Method, p = 0.10).
This means that the automated method is performing equally well as the two human
observers. However, the low p value indicates that significant interaction effects may
be present. It appears that there is some dependency of the performance of the
automated method on the time point since the automated method is significantly
different from the human observers at T0 and T2. Visual inspection of Figure 3.6 (top
right) suggests overestimation of the volume at T0 and underestimation of the volume
at T2. There is no significant difference at T1. This is supported by the Bland-
Altman plots (Figure 3.5, bottom row) in which the mean difference in measurement
is close to zero at T1. However, these differences are borderline and probably due to
the very small variation between the human observers.
The bone volumes of pathologic bones were significantly decreased compared to
the healthy bones at T2 (Figure 3.6, top left). There are no significant differences at
T0 and T1. There are two explanations why there is no volume decrease at earlier
time points. Firstly, the bone marrow is partially flushed out of the bone during the
intra osseous injection of tumor cells. This partial bone marrow ablation has profound
anabolic effects on local bone turnover. Bone formation induced by bone marrow
ablation reaches a maximum of 1 week after the intervention. After this initial
week, the bone volume normalizes gradually over time as the bone recovers from the
procedure, a process that can take weeks.18,19 Secondly, starting osteolytic lesions
around the tumor create weak areas in the bone. The mechanical stress on other
healthy parts of the bone will increase due to these weak areas. Both the anabolic
effects due to the partial bone marrow ablation and due to the increased mechanical
stress result in a local increase of bone volume alongside osteolytic lesions. Combined,
these anabolic and osteolytic processes influence the volume measurements as can be
seen in Figure 3.6 (middle and bottom rows, a–d and f). The cortical thickness maps
provide an excellent tool to see exactly where the volume changes occur in relation
to the osteolytic lesion site (Figure 4.4).
The presented segmentation method is not restricted to the tibia, but can be ap-
plied to any bone of the skeleton in whole-body µCT scans, as long as it is contained
in the MOBY mouse atlas.7,9,20 We are currently implementing the volume measure-
ments of every segmented skeletal element using the same principle. We segmented
the femur as preliminary proof of concept. Several conclusions can be drawn from
the results in Figure 3.7. The volumes of the right and the left femur are very similar
for the manual and the automated measurement, meaning that measuring the femur
is highly reproducible. The automated method, however, underestimates the volume
compared the manual method. This underestimation is to be expected since the fe-
mur included in the MOBY mouse atlas does not include the femoral head and neck.
Therefore the segmentation result “cuts” the femoral neck approximately in the mid-
dle and the amount of underestimated volume thus corresponds to the volume of the
femoral head and part of the femoral neck. Note that this is a systematic error and
only leads to inaccurate results if the femoral head and neck are of particular interest
within a study. The same type of measurement error may occur for other bones as
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well, since most of the bones in the MOBY atlas are simplified versions of the real
bone shape. However, as is the case for the femur, this should not lead to problems
because the error is systematic. In the cases where higher segmentation accuracies
are required in a particular part of the bone that is simplified, another animal model
with more details could be employed. One should however bear in mind that using
simplified bone shapes has the advantage that the influence of, e.g., differences in
strain or animal size can be minimized by leaving out the fine details.
The increased radiation dose of µCT compared with radiographs has always been
a major concern limiting its use in cancer research. This is not a problem anymore
as modern µCT scanners can perform whole-body scans in less than a minute.21 The
delivered radiation dose during these scans is well below a dose that would affect
tumor growth, even during longitudinal follow-up studies.21–23
All datasets used in this article have been generated with a standard scanning
protocol using the Skyscan 1076 µCT. However, the described methods can be per-
formed on any other whole-body µCT dataset acquired on a different machine and
with a different protocol. Other scans might require an adjustment of threshold
values and the initial scan resolution will always be a limiting factor during further
analysis.
Finally, we want to stress that the described method is general and can be applied
to others species as well. The only prerequisite is that an anatomical skeleton atlas
is available for the animal of interest.
Conclusion
We suggested a new µCT analysis paradigm based on the combined approach of pre-
viously published methods for animal posture correction, normalized visualization
of follow-up data, and the quantification and visualizations discussed in this paper.
Together, this results in a fast and automated workflow, in which the user can easily
compare whole-body µCT scans on the whole-body level, zoom in to the level of a
single bone or bone segment of choice, and gain qualitative and quantitative data
of that segment. The animals can be scanned in any posture. Normalized and in-
teractive side-by-side visualizations of the exact same section of skeletal elements at
different time points can be generated from longitudinal scans in which one animal
is scanned multiple times over time. The detailed side-by-side visualizations greatly
help the researcher to identify changes in the skeleton. The researcher can then iden-
tify and zoom in on the bone or bone segment of interest and automatically generate
quantitative volumetric data alongside visualizations of the segmented volume and
visualizations of the cortical thickness of that specific skeletal element. This new
workflow greatly reduces analysis time, aids the handling of complicated scan data
and improves the overall qualitative and quantitative assessment of µCT scans. The
method was validated by quantification of osteolytic effects over time in the tibia but
can easily be adapted to other bones of the skeleton. In addition, the approach can
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submitted
1Dept. of Endocrinology, LUMC, Leiden, The Netherlands
2Dept. of Radiology, Division of Image Processing LKEB, LUMC, Leiden, The Netherlands
3ICT Group, Dept. of Mediamatics, Delft University of Technology, Delft, The Netherlands
66 Chapter 4
Abstract
The pathogenesis of bone metastases is a complex and multifaceted process. Often
multiple imaging modalities are needed to follow both the structural and functional
changes over time during metastatic bone disease. Researchers face extended datasets
of one experiment acquired with multiple modalities at multiple points in time. This
review gives an overview of an integrated approach for handling this kind of complex
data. It focuses on the analysis of whole-body µCT and optical data handling. We
show how researchers can generate side-by-side visualizations of scans taken with one
imaging modality at multiple time points and with multiple modalities at one time
point. Moreover we highlight methods for normalized volumes of interest selection
and quantification of bone volume and thickness.
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Introduction
Bone is one of the preferred sites of breast cancer and prostate cancer metastases.
Post mortem examination revealed that approximately 70% of patients who died of
breast or prostate cancer carried bone metastases.1 The attraction of certain types
of cancer towards bone was already noted in 1889 by Stephen Paget2 and has been
well studied ever since.
The clinical manifestations of overt bone metastases are vast, ranging from se-
vere osteolysis to osteoblastic calcifications outside the bone and inside the marrow
cavity.3 Bone metastases are a clinical predictor of poor survival for both breast and
prostate cancer patients. The pathology of this so called metastatic bone disease is a
result of a complex interactions between the tumor and the bone micro-environment.
The crosstalk between the tumor and bone results in the disruption of the delicate
balance between osteoclasts and osteoblasts.4,5
Key regulators involved in osteolytic bone metastases are parathyroid hormone
related protein (PTHrP) produced by the tumor and transforming growth factor-
β (TGF-β) released from the bone upon resorption. PTHrP stimulates osteoclas-
togenesis and prolongs osteoclast survival. The released TGF-β stimulates PTHrP
production by the tumor. It furthermore stimulates proliferation and apoptosis resis-
tance together with other growth factors which are released from the resorbed bone
matrix. This positive feedback loop is known as the vicious cycle of osteolytic bone
metastases.4,5
Bone metastases are difficult to treat because of the strong positive feedback loop
between the tumor and the bone micro-environment. Research towards treatment
of bone metastases is in need of reliable methods to quantify bone specific effects of
experimental treatments in vivo. Imaging can be an informative tool for that purpose,
providing qualitative as well as quantitative results. Here we give an overview of both
the structural and functional whole-body imaging modalities which can be used in
research on metastatic bone disease as well as on other bone related diseases. We
will focus on recent advances in normalized comparison of datasets of one animal
made at different points in time and combining data generated with multiple imaging
modalities.
Structural Imaging
Pre-clinical imaging modalities can be grouped in two classes, structural imaging
modalities such as X-ray based imaging and functional imaging modalities such as
bioluminescence imaging (BLI), fluorescence imaging (FLI), positron emission topog-
raphy (PET) and single photon emission computed tomography (SPECT). Structural
imaging modalities are used to visualize and quantify structural and architectural
features of the skeleton, whereas functional imaging modalities are used to gain in-
sight in cellular, metabolic and molecular processes within and around cancerous
bone lesions. Since decades, structural imaging of bone and bone lesions has been
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Figure 4.1: Aligning the articulated atlas with µCT data. Registration results between the atlas
(red) and two different subjects (grey) after coarsely aligning the skeleton (top), after the
articulated registration (middle), and after organ approximation (bottom). Adapted with
permission from8
performed with radiography. The advances in digital computing enabled the develop-
ment of three dimensional (3D) computed tomography (CT) by Godfrey Hounsfield
during the 1970s which was a major revolution in the field of X-ray based imaging.6,7
Nowadays, specialized micro-CT (µCT) scanners are available for small laboratory
animals with resolutions of several micrometers.
Posture Correction
The posture of entire animals varies greatly between scans taken at multiple time
points. As a result, it can be difficult to identify small osteolytic lesions in longitudinal
µCT datasets, even for an experienced observer.9 For some applications, dedicated
animal holders can be used to reduce the postural variability,10 but such holders are
often not sufficient and limit the throughput, especially for multi-modality studies.
Therefor, compensation for large posture variations between scans taken at different
time points is needed, to enable the user to identify small lesions within these large,
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Figure 4.2: Demonstration of mapping the skeletons of four different animals to a common
reference domain. The large postural differences of the animals (left) are not present
anymore (right), enabling a more intuitive comparison of different time points. Adapted
with permission from8
complex whole-body µCT datasets.
To compensate for the postural differences between scans, a method has been
developed based on matching an atlas to whole-body µCT datasets. For this purpose
Khmelinskii et al. developed kinetic mouse and rat atlases. The skeletons of these
atlases have been segmented and each individual skeletal element has been identified.
In addition, each joint position has been annotated and the kinetic degrees of freedom
have been specified.8 The posture of such an articulated atlas can be changed to fit
the skeleton of an actual animal µCT scan. Also, the positions of major internal
organs without µCT contrast are approximated based on the positions of the skeletal
elements, lungs and skin (Figure 4.1).9 Baiker et al. developed a fully automated
system for aligning the atlas with µCT scans. The automated system can effectively
perform posture corrections in the absence of soft-tissue contrast in in vivo µCT data
and without requiring user initialization. The approach is robust with respect to large
postural variations and to moderate, pathology-induced structural variations.9 After
aligning the atlas with the scan data, the skeletal elements of the scanned animal can
be repositioned to a standardized posture. This articulated atlas-based repositioning
of the skeleton facilitates fast data comparison (Figure 4.2).8
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Side-by-side Visualizations
Intra-cardiac injection of bone specific MDA-MB-231 breast cancer cells is a popu-
lar method to induce osteolytic cancer metastases in the skeleton. Bone metastases
will develop at several sites throughout the skeleton within one to three weeks after
inoculation with cancer cells. Disease progression of these osteolytic lesions can be
followed by comparing whole body µCT scans taken at different time points. How-
ever, the initial structural disease induced changes in this kind of follow-up datasets
can be very small and difficult to identify in complex 3D datasets. Posture normal-
ization of the datasets is helpful, but often not enough. Kok et al. developed an
approach which enables side-by-side visualizations of an individual skeletal element
at different time points. The data used for these detailed visualizations is extracted
from longitudinal whole-body µCT datasets.11
The generation of side-by-side visualizations individual skeletal elements is a
multi-step process. First, the µCT datasets taken at each time point are aligned.
Next, the scan is divided in normalized sub-volumes which are placed around each
of the skeletal elements. These sub-volumes are then used to generate an “exploded
view” (Figure 4.3a) of the skeleton. Finally, the sub-volumes are mapped into a
common reference frame using articulated planar reformation (APR), where corre-
sponding volumes of interest (VOIs) are visualized side-by-side (Figure 4.3b-c). The
visualizations of the different time points are coupled, in other words, the user selects
a section or visualization of a skeletal element of a scan taken at one time point and
the system will automatically generate the corresponding visualization of the other
time points.11
Methods of mapping data into a common reference frame make the use of animal
holders during data acquisition obsolete because postural differences can be com-
pensated for afterwards. The use of sub-volumes per skeletal element not only has
the advantage of aligning structures of interest between time-points, it also enables
data analysis at full resolution because only a small part of the whole-body dataset
is loaded. This is often not possible for whole-body datasets because of the extreme
computing requirements due to the large amount of data.
Quantification
Treatment and intervention studies on bone metastases often require the quantifica-
tion of several bone parameters. Currently, the quantification of osteolytic lesions is
performed by drawing a region of interest (ROI) around the lesion on two dimen-
sional (2D) radiographs and measuring the lesion surface.12,13 Lesions projected on
top of each other and lesions on the side of bone will be underestimated when quan-
tified due to the flattening of the 3D structure (Figure 2.6).14 The large dependency
on manual input results in a strong dependence on experience of the observer and
makes the method prone to observer bias. The scoring of such radiographs cannot
be automated due to variability of shape and grey-values between various bones and
lesions.




Figure 4.3: Exploded view and side-by-side visualizations of longitudinal µCT data. Osteolytic
bone metastases were induced by intra-cardiac injection of 1 · 106 MDA-MB231-BO2 cells
(an osteolytic, bone specific subclone of the MDA breast carcinoma cell line) in a 6 week
old nude mice. µCT scans were made 3, 5 and 6 weeks after inoculation. The animal was
scanned in a different posture per time-point, supine (week 3) and prone (week 5 and 6).
(a) Longitudinal µCT data has been aligned with the articulated mouse atlas to eliminate
differences in posture. Next, the scans were divided over sub-volumes per skeletal element.
Structural changes between time points have been highlighted. These areas are potentially
interesting to the user for further, in depth, inspection. The femur has been selected and is
shown side-by-side in detailed views for the three available time points at 3, 5 and 6 weeks
into the experiment (b) and (c). Shown for each time point are an image plane that can
be interactively moved through the volume (b) and a surface rendering of the entire femur
(c). At 5 and 6 weeks, bone resorption can clearly be seen near the knee area (indicated
by the arrows), even though the animal posture in the original data was highly variable.
Note that between the first and second time point, with the subject at 10 and 12 weeks of
age respectively, some growth is still taking place, which has to be taken into account when
analyzing the images. Figure adapted with permission form11
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µCT is a 3D modality and therefore datasets provide more accurate information
on disease induced changes like an increase or decrease in bone volume, bone thickness
and bone density, both for visual and quantitative assessment. However, the selection
of a VOI in 3D datasets is more complex than ROI selection in 2D data.
A multi-planar reformation (MPR) based approach for normalized selection of
VOIs in complex 3D shapes has been published (Chapter 2).14 The approach makes
use of a center-line which has been fitted through an individual bone. This naturally
curved center-line can then be “straightened” to generate a new, normalized volume.
The straightened bone is orientated along the z-axis of this new volume. The volume
can then be used to extract normalized cross-sections or to define a normalized VOI
(Figure 2.2). The selected VOI is mapped back to the original scan volume, where
the actual volume measurements are performed. This way, the volume measurements
are not influenced by introduced artifacts due to the straightening procedure. The
VOIs selected following this method are predefined and relative to the anatomy of
the bone. This way, the VOI selection is independent of the observer, reducing the
chance of observer bias. Moreover, it becomes possible to select exactly the same
part of multiple bones, enabling data comparison between multiple scans.14 This
approach has been automated and integrated it in the exploded view visualization
system (Chapter 3).15
In addition to volume measurements, µCT scans can be used to determine cor-
tical bone thickness. This type of measurements were added to the exploded view
workflow. The cortical thickness is measured and projected as a color code on a
volume rendering of the bone. Figure 4.4 shows an example of such thickness maps.
In this example, osteolytic breast cancer cells were inoculated in the tibia of nude
mice. There is an initial increase in cortical bone thickness around the lesion. After
this initial increase, the bone disappears as the local tumor grows and stimulates
osteolysis.15 These kind of visualizations are, like volume measurements, of use for
the evaluation of both osteolytic and osteosclerotic lesions.
Altogether, the automated workflow for whole-body µCT scans described above
enables the user to select and zoom in on each individual skeletal elements, visually
assess structural changes over time of the selected bone and quantify the volumes of
pre-defined VOIs within that bone. µCT provides excellent structural and volumetric
information and can be used to track changes over time, however this modality is
limited to tissues with a high X-ray contrast.
Functional Imaging
Functional imaging modalities are used to gain an insight in cellular, metabolic and
molecular processes. Functional imaging includes not only optical imaging modalities
such as BLI and FLI but also MRI and radioactive imaging methods such as PET
and SPECT.
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Figure 4.4: Cortical thickness maps. MDA-231-B/luc+ cells (2.5 · 105 cells) were inoculated directly
into the right tibia of a 6 week old female nude mouse. Whole-body µCT scans were made
before inoculation (T0), 3 weeks after inoculation (T1) and 6 weeks after inoculation (T2).
The measured cortical thickness is mapped to surface representations of tibia, by means of a
colormap. The initial osteolytic lesion is surrounded by an area of increased bone thickness
at T1. The increased thickness is mainly a result of the inoculation procedure. Most of the
cortical bone has disappeared at T2. This method of evaluating bone thickness can only be
used for cortical bone and not at the distal part of the femur or the proximal part of the tibia




Optical imaging modalities are based on capturing photons in the visible and near
infrared (NIR) part of the spectrum originating from cells and tissues. These photons
can be produced by either fluorescence or bioluminescent enzymatic reactions. The
choice between using fluorescence or bioluminescence greatly depends on the research
question. Bioluminescence gives an indiction of cell metabolic activity or activation
of certain signaling cascades whereas fluorescence can be used for imaging of cell
tracking and enzymatic activity.
BLI is most commonly used to follow in vivo tumor growth of luciferase expressing
tumor cells over time.16 In addition, there are a number of transgenic animal mod-
els expressing luciferase under tissue specific promotors such as the prostate specific
PSA-Luc mouse17 and transgenic animals that lumines upon upregulation or acti-
vation of certain signaling cascades such as the VEGF receptor 2 luciferase mouse
(FVB/N-Tg-(VEGFR2-Luc)-Xen).18
FLI can be used for tracking of cells expressing certain fluorescent proteins. Other
approaches to FLI make use of targeted fluorescent dyes or probes which fluorescence
upon enzymatic activation such as the matrix metalloproteinase specific MMPSense
(PerkinElmer)19 and various cysteine proteinase activity-based probes (APBs).20–24
The fluorophore of ABPs binds specifically and covalently to the active domain pro-
teases. The fluorescence can be monitored in vivo, but can also be detected in
histology can sections or on western blots because of the covalent bond. This en-
ables the exact ex vivo validation and quantification of the signal after the in vivo
study. Two other fluorescent probes of interest to the cancer and bone field are Os-
teoSense (PerkinElmer)25 and BoneTag (LI-COR),26,27 both commercially available
dyes, which bind specifically to bone at areas of high turnover such as osteolytic and
osteosclerotic lesion sites.
BLI and FLI are essentially 2D modalities. However, recent developments in
imaging equipment enabled 3-dimensional data capturing and reconstruction. The
technological advancements of optical imaging and the use of optical imaging in the
field of bone research have been reviewed in detail by Snoeks et al.27
PET, SPECT and MRI
PET and SPECT are two closely related radioisotope imaging modalities. Most
modern animal PET and SPECT scanner are combined with a CT scanner to pro-
vide more structural information. The use of PET and SPECT is limited to a few
institutions because of the infrastructure, which is needed for the complicated han-
dling of radio tracers. There is a multitude of radio tracers, which can be used
to image and quantify various targets in metastatic bone. Most common are the
clinically used radioactive labeled bisphosphonates to assess local hotspots in bone
turnover,28,29 αvβ3 integrin targeted tracers to measure endothelial cell activation30
and radiolabeled deoxyglucose to image areas of high metabolic activity such as tu-
mors and inflammation.29,31–33 Both PET and SPECT offer excellent quantification
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possibilities but are limited in anatomical and spacial contrast.
Of the functional imaging approaches, MRI is the modality that gives the best
anatomical and soft tissue contrast without the use of ionizing radiation. It was first
used to image and quantify diffuse bone metastases with and without osteolysis.34
Later measurements of cortical bone thickness were included in MRI analysis to
be able to quantify osteolysis in addition to the tumor size.35 Recently, Bauerle
et al. described a more integrated approach.36 They combined MRI quantification
of the tumor size with volumetric measurements performed with µCT. In addition,
they performed vessel size imaging, blood volume measurements and measurements
regarding the cellularity of the tumor lesions. This combination of µCT with various
MRI-based measurements provides complementary information on tumor growth,
angiogenesis and vascularization, bone destruction and the morphological state of
the tumor, and it can be used to follow changes over time and treatment response.36
Integrated Approaches
Imaging can be used to visualize and quantify both structural and functional char-
acteristics of tumors and tissues in vivo. Every modality has its own strengths and
weaknesses. It is key to combine the data acquired with each modality in order to
come to a complete understanding of the disease process or treatment effects. In or-
der to do that, an integrated approach is needed which maps all the data generated
with various modalities throughout an experiment and align this data in space and
time (Figure 4.5).
The newly developed 3D optical data capturing techniques and subsequent optical
3D datasets allow for projection of this data on more structural modalities such as
µCT (figure 4.6a-c).16,27 Optical modalities such as BLI completely lack structural
information other than the skin. This is the reason why it is important to acquire the
optical data together with structural data like µCT in the same posture to assure
a good estimation of the signal source location. The optical data, coupled to the
µCT data, can then be handled in the same workflow as the other modalities.
MRI and SPECT datasets contain enough anatomical data to be able to fit the
articulated atlas.8,38 These datasets can then be handled in a similar fashion as the
µCT data. This enables not only side-by-side visualizations of data generated with
one modality at different time-points (as is the case in Figure 4.3) but also side-by-side
visualizations of data generated at one time-point with different modalities (figure
4.6d-f).37,38 The data is semi interactive; the user can select a certain field of view
in one dataset and the corresponding field of view will be automatically generated in
the datasets of the other modalities.
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Figure 4.5: Overview of the integrated data workflow. The data generated at different points in
time using different modalities is mapped to a common reference frame based on an artic-
ulated animal atlas. The atlas is then used to reposition the animal and divide the large
datasets in smaller normalized sub volumes. This enables normalized whole-body data eval-
uation, side-by-side visualizations of a VOI with data generated using multiple modalities at
one time-point, side-by-side visualizations of a VOI with data generated using one modality
at different time points and various quantifications per modality.




Figure 4.6: Multi-modality visualization of bone metastasis. (a) MDA-231-B/luc+ cells (2.5 · 105
cells) were inoculated directly into the right tibia of a 6 week old female nude mouse. Three
weeks after tumor cell inoculation, bone metastases where analyzed with an IVIS 3D BLI
Imaging system (Caliper Life Sciences, Alameda, CA). The animal was subsequently scanned
in a SkyScan 1076 µCT scanner (SkyScan, Kontich, Belgium) in the same position as during
the BLI measurement. Left: The bioluminescent data captured from 8 positions around the
animal was reconstructed and projected back onto a CT reconstruction of the animal. Middle:
Detail of the CT volume visualization of the right hind limb. Right: The tumor induced
osteolytic lesion is clearly visible. Detail of the BLI tumor volume estimation projected
onto the CT reconstruction. The source of the bioluminescent signal co-localizes with the
osteolytic lesion site. Adapted with permission from27. (b) Animals imaged with CT,
MRI and SPECT at one time point. The articulated atlas has been fit to the scan data
(middle row) and side-by-side visualizations of one specific segment have been generated
using the atlas-based planar reformation approach. In the near future it will be possible to




The integrated data handling in which all datasets from an experiment are mapped
into one common reference frame, as summarized in Figure 4.5, enables the user to
explore the data in an intuitive way. The user can assess disease induced lesions by
generating side-by-side views of changes over time in one skeletal element. A greater
understanding of what is happening in a diseased area of the animal is achieved by
combining functional and structural data acquired with various imaging modalities.
Recently a start has been made to implement detailed quantifications, such as
bone volume and thickness, into this workflow. This facilitates the objective moni-
toring of disease induced lesions and the effectiveness of treatment interventions. The
detailed quantitative assessment of optical data is still a challenge. The development
of whole body articulated atlases containing information on optical properties of var-
ious tissues might facilitate the development of better signal quantification methods.
The overall logic and workflow of integrated data handling can serve as a vehicle to
implement this kind of future developments.
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Abstract
In anti-cancer therapy, current investigations explore the possibility of two different
strategies to target tumor vasculature; one aims at interfering with angiogenesis, the
process involving the outgrowth of new blood vessels from pre-existing vessels, while
the other directs at affecting the already established tumor vasculature. However,
the majority of in vitro model systems currently available examine the process of an-
giogenesis, while the current focus in anti-vascular therapies moves towards exploring
the benefit of targeting established vasculature as well. This urges the need for in
vitro systems that are able to differentiate between the effects of compounds on an-
giogenesis as well as on established vasculature. To achieve this, we developed an in
vitro model in which effects of compounds on different vascular targets can be stud-
ied specifically. Using this model, we examined the actions of the fumagillin derivate
TNP-470, the matrix metalloproteinase inhibitor marimastat and the recently de-
veloped tubulin-binding agent Ang-510. We show that TNP-470 and marimastat
solely inhibited angiogenesis, whereas Ang-510 potently inhibited angiogenesis and
caused massive disruption of newly established vasculature. We show that the use
of this in vitro model allows for specific and efficient screening of the effects of com-
pounds on different vascular targets, which may facilitate the identification of agents
with potential clinical benefit. The indicated differences in the mode of action be-
tween marimastat, TNP-470 and Ang-510 to target vasculature are illustrative for
this approach.
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Introduction
A functioning and continuously expanding vascular network is essential for tumor de-
velopment, growth, survival and metastasis. Given its pivotal role in these processes,
tumor vasculature is a highly attractive target in anti-cancer therapy. Moreover,
anti-vascular treatment may present with a low risk of developing drug resistance
and promises to be effective against a broad spectrum of tumors.1,2 Currently, two
key approaches to target the tumor’s blood vessel network have been developed.3,4
One is directed at interfering with angiogenesis while the other aims to affect the
already established tumor vasculature.
Angiogenesis is the process involving the outgrowth of new blood vessels from pre-
existing vessels, and many compounds that affect tumor angiogenesis in vitro have
been identified and are currently being investigated in clinical trials. Anti-angiogenic
agents that have been tested interfere with different targets, such as angiogenic stim-
uli, receptor activity and endothelial cells.4–6 The second approach aims at prefer-
ential targeting of the already established tumor vascular network and makes use of
so-called vascular-disruptive agents (VDAs).7–9 All VDAs currently examined draw
on the differences between tumor and healthy vasculature to allow for highly selective
targeting of tumor blood vessels.10,11
The VDAs can be divided into two categories: biologic and small-molecule agents
(SMAs). Biologic agents include peptides and antibodies that deliver effectors to the
tumor endothelium, where SMAs exploit the differences between healthy and tumor
vasculature to induce selective vascular dysfunction.12–14 Targeting angiogenesis and
already established vasculature could both have their role in anti-cancer therapy.
Where tumor angiogenesis is well suited for treating micrometastatic disease and
early-stage cancer, disrupting established tumor vasculature leads to rapid vascu-
lar collapse, vessel congestion and tumor necrosis and is therefore more efficacious
against large, already established tumors. Both approaches have shown promising
results in ongoing preclinical studies, but treatments either targeting tumor angio-
genesis or established tumor vasculature alone are not fully effective.10,15–19 For this
reason, current research explores the benefit of combining these anti-vascular treat-
ment strategies.13,20–22
When developing new anti-vascular compounds it would be of great benefit if one
could determine if the overall anti-vascular action is mainly due to effects on inhibition
of angiogenesis or to suppression of established vasculature or a combination of both.
Therefore, in the present study, we developed an assay in which effects of substances
on angiogenesis can easily be studied next to those on established vasculature in the
same in vitro model. In order to validate this model system, we examined the actions
of a number of different anti-vascular agents, among which a recently developed









Figure 5.1: Chemical structure of the tubulin-binding agent Ang-510.
Materials & methods
Chemicals & reagents
Culture medium was α-MEM from Gibco BRL, Breda, The Netherlands, supple-
mented with 10% fetal calf serum (FCS) and penicillin/streptomycin. rhVEGF-A
was from Oncogene, Sanbio, Uden, The Netherlands. ER-MP12 directed against
murine PECAM-1 (CD31) was kindly provided by Dr. P. Leenen, Erasmus Univer-
sity, Rotterdam, The Netherlands. The matrix metalloproteinase (MMP)-inhibitor
marimastat was kindly provided by Chiroscience Inc. (Cambridge, United Kingdom).
TNP-470, a kind gift from W. Landuyt, University Hospital, K.U. Leuven, Belgium.
The newly developed tubulin-binding agent Ang-510 was a kind gift from Graeme
J. Dougherty and Peter D. Davis, Angiogene Pharmaceuticals Ltd. (United King-
dom).
In vitro vascularization models
In vitro angiogenesis was measured as outgrowth of endothelial capillary structures
from cultures of 17-day-old fetal mouse metatarsal bone explants, as described pre-
viously.23 In short, isolated metatarsals were cultured for 48h in 24-well plates in
125µl α-MEM medium to allow for attachment to bottom of the culture plate. Sub-
sequently, medium was replaced by 500µl fresh medium containing vascular endothe-
lial growth factor (VEGF) (50ng/ml) and the test substances and the medium was
replaced every 3-4 days. After a total of 10 days of culture, the explants were fixed
and stained for PECAM-1.
In the pre-culture experiments, the explants were treated for 24h with the test
substances, after attachment to the bottom of the plate, and were subsequently
cultured for another 10 days in the presence of VEGF (50ng/ml).
The area of PECAM-1-positive tubular structures was determined by image anal-
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ysis using Image Pro Plus 3.0 for Windows 95/NT (Media Cybernetics, Carlsbad,
CA). Images were obtained using a digital camera with a fixed window of 768 × 576
pixels. Data are depicted as number of pixels per area.
In vitro effects on newly established vasculature were examined in fetal mouse
bone explant cultures that were first cultured for 10 days in the presence of VEGF
(50ng/ml) to stimulate capillary network formation. Subsequently, the medium was
replaced with 500µl fresh medium containing the test substances and were cultured
for another 24h after which they were fixed and stained for PECAM-1 and further an-
alyzed as described above. After obtaining images for the quantification of PECAM-1
positive structures, the cultures were counterstained with Mayer’s hematoxylin (H)
for 30 seconds and eosin (1% in 96% ethanol) (E) for 90 seconds.
Statistics. Results are depicted as mean value standard error of the mean (SEM).
Differences between groups were determined by one-way analysis of variance for mul-
tiple comparisons followed by Fisher’s LSD test.
Results
Effects on angiogenesis
Figure 5.2a shows dose-inhibition curves of the effects of marimastat, TNP-470 and
Ang-510 on VEGF (50ng/ml) stimulated PECAM-1 positive capillary outgrowth
from 17-day-old fetal mouse metatarsal bone organ cultures. VEGF-stimulated out-
growth was significantly and dose-dependently suppressed by marimastat, TNP-470
and Ang-510 with IC50 values of approximately 0.6, 0.6 and 0.06µM, respectively.
The effects of these agents on endothelial outgrowth are further illustrated in Figure
5.2b–d. Figure 5.2b shows a large PECAM-1 positive endothelial network that has
been formed after 10 days stimulation with VEGF. Figure 5.2c and d show VEGF-
stimulated cultures in the presence of 1µM TNP-470 and 1µM Ang-510, respectively.
Both compounds inhibited the outgrowth of a capillary network, with Ang-510 being
more potent than TNP-470. Explants cultured with 1µM marimastat showed inhi-
bition of vascular outgrowth, similar to those treated with TNP-470 (not shown).
In order to study the effect of the three agents in our anti-angiogenic model in
more detail, we examined the effect of pre-treatment with these agents on subse-
quent VEGF-stimulated vascular outgrowth. At time of explantation, PECAM-1
positive endothelial precursor cells are located in the perichondrium of the explants,
as previously shown.23 From these precursor cells the capillary structures sprout and
form the vascular network. To target these precursor cells, directly after adhesion
to the culture plate, the fetal bone explants were pre-treated for 24 h with the dif-
ferent anti-vascular compounds and were than subsequently cultured for 10 days in
the presence of VEGF. As shown in Figure 5.3, pre-treatment with marimastat did
not affect VEGF-stimulated capillary outgrowth, while both TNP-470 and Ang-510
significantly suppressed subsequent VEGF-stimulated outgrowth with IC50 values of
approximately 0.7 and 0.08µM, respectively.
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Figure 5.2: Effects on angiogenesis. (a) 17-day-old fetal mouse bone explants were stimulated for 10
days with VEGF (50ng/ml) in the absence or presence of different concentrations marimastat,
TNP-470 or Ang-510 (n = 6). Quantification of the number of PECAM-1 positive pixels
per area is given as mean ± SEM (∗p < 0.05; ∗ ∗ p < 0.01 compared to controls). (b–d)
Endothelial outgrowth after stimulation with VEGF (b) and after simulation with VEGF
together with TNP-470 (1µM) (c) and together with Ang-510 (1µM) (d).
Effects on newly established vasculature
To study the effects of the three compounds on newly established capillaries, first
endothelial outgrowth was stimulated with VEGF (50ng/ml) for 10 days and subse-
quently the cultures were treated for 24h with the different anti-vascular agents. As
shown in Figure 5.4a, marimastat and TNP-470 did not affect the VEGF-stimulated
newly formed vasculature while Ang-510 showed a significant suppression of newly
established vasculature with an IC50 of around 0.01µM.
Figure 5.4b shows control capillary outgrowth after 10 days stimulation with
VEGF, stained for PECAM-1 and counter stained with HE. Figure 5.4c and d depicts
newly formed vasculature after subsequent 24h treatment with TNP-470 (10µM) and
Ang-510 (1µM). As shown, TNP-470 did not affect the established capillary network,
similar results were obtained with marimastat (10µM) (not shown). In contrast, 24h
treatment with Ang-510 caused a significant disintegration of the newly established
capillary structures, with only fragments of the original network remaining. Histo-
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Figure 5.3: Effects of pre-treatment on vascular outgrowth. 17-day-old fetal mouse bone explants
were, directly after adhesion to the culture plate, cultured for 24h with different concentra-
tions of marimastat, TNP-470 or Ang-510 and subsequently stimulated for another 10 days
with VEGF (50ng/ml) (n = 6). Quantification of the number of PECAM-1 positive pixels
per area is given as mean ± SEM (∗p < 0.05; ∗ ∗ p < 0.01 compared to controls).
logical HE staining revealed that this degenerative effect was specific for the capillary
network, as the layer of fibroblastic cells, originating from the periosteum on which
the capillary network grows and expands,23 remained morphologically fully intact.
Discussion
In this study, we developed an in vitro model that can distinguish between effects of
compounds on angiogenesis and on newly established vasculature. We examined the
effects of three anti-vascular agents, among which the recently developed tubulin-
binding agent Ang-510. We showed that this compound effectively interfered with
both angiogenesis as well as newly established vasculature, whereas the synthetic
fumagillin derivate TNP-470 and the MMP-inhibitor marimastat selectively affected
angiogenesis alone.
Angiogenesis is the process of generating new blood vessels from pre-existing vas-
culature, which is indispensable for solid tumor growth and metastasis. As such,
targeting tumor angiogenesis, in anti-cancer therapy, is an intense field of interest.
Current investigations towards the development of agents that inhibit tumor vascu-
larization, however, not only focus on interference with the process of angiogenesis,
but also on intervention with already established tumor vasculature.3,4 Compounds
that belong to this group are called VDAs; agents that selectively target tumor vas-
culature on basis of structural and functional abnormalities of these vessels.7–9 In
the development of new and more effective anti-vascular agents, it is of importance
to have model systems available that can give accurate information about their mode
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Figure 5.4: Effects on newly established vasculature. (a) 17-day-old fetal mouse bone explants
were stimulated for 10 days with VEGF (50ng/ml) followed by 24h treatment with different
concentrations marimastat, TNP-470 or Ang-510 (n = 6). Quantification of the number of
PECAM-1 positive pixels per area is given as mean ± SEM (∗p < 0.05; ∗∗p < 0.01 compared
to controls). After culture, bone explant capillary outgrowth was visualized by staining
for PECAM-1 in combination with HE. (b–d) The combined PECAM-1 and HE staining
are shown for explants stimulated for 10 days with VEGF without subsequent treatment
(control) (b), and for explants stimulated with VEGF with subsequent 24h treatment with
TNP-470 (10µM) (c) or Ang-510 (1µM) (d).
of action and vascular targets involved and thus can differentiate between effects on
angiogenesis or newly established vasculature. For this, we adapted our previously
developed angiogenesis assay consisting of the outgrowth of capillaries from cultured
fetal mouse metatarsals and suited it to study effects on established vasculature as
well.23 To validate this in vitro model, we examined the effects of three different
compounds in several experimental settings.
We examined the anti-angiogenic actions of two well-known inhibitors of angio-
genesis, marimastat and TNP-470, respectively, and that of the newly developed
tubulin-binding agent Ang-510. In previous studies, it has been shown that both
the synthetic MMP-inhibitor marimastat, as well as the synthetic fumagillin derivate
TNP-470 possess strong anti-angiogenic properties in various in vitro models by in-
terfering with endothelial cell invasion and proliferation.24–28 In concordance with
these observations, in our model, marimastat and TNP-470 potently and dose de-
pendently inhibited angiogenesis, indicated by suppressed outgrowth of PECAM-1
positive capillaries. Moreover, the newly developed tubulin-binding agent Ang-510
also showed strong anti-angiogenic properties in our model system.
Previously, we have shown that PECAM-1 positive endothelial precursor cells are
present in the perichondrium of the bone explants, before the outgrowth of vascu-
lature.23 In order to determine whether the observed anti-angiogenic effects might
involve a direct action on these early-stage endothelial precursor cells from which
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the capillaries are formed, we pre-incubated the bone explants with the different
agents for 24h and subsequently cultured them for 10 days in the presence of VEGF.
After pre-treatment of the bone explants with marimastat, at doses that actively sup-
pressed angiogenesis, there was no effect on the subsequent outgrowth of vasculature.
Recent studies have shown that MMP-inhibitors such as marimastat inhibit angiogen-
esis by blocking the invasion and migration of endothelial cells into the extracellular
matrix,24,29,30 which might explain why in our model, marimastat does not have a
direct effect on endothelial precursors and their subsequent vascular outgrowth after
pre-treatment, but strongly inhibits angiogenesis when it is continuously present. In
line with this, it was previously shown that in a three-dimensional rat aortic model,
marimastat potently inhibited angiogenesis, without affecting the proliferation of rat
aortic endothelial cells in monolayer cultures.24
In contrast to marimastat, TNP-470, and even more potently Ang-510, inhib-
ited vascular outgrowth after 24h pre-treatment of the bone explants. TNP-470 is a
known angiogenesis inhibitor, which has been shown to induce a cell cycle arrest in
the G1-phase, resulting in inhibition of endothelial cell proliferation and network for-
mation, indicating that this compound acts via a cytostatic rather than a cytotoxic
mode of action.25–28 However, in our model, at higher concentrations, inhibition
of outgrowth of vasculature by TNP-470 was not reversible after stimulation with
VEGF, suggesting that, at these doses, the mode of action is cytotoxic and not cy-
tostatic. Interestingly, a similar dual mode of action of TNP-470 has been described
on the in vitro growth of human umbilical vein endothelial cells (HUVECs), showing
cytostatic inhibition at lower doses and a cytotoxic suppression at higher doses.31
Furthermore, we found that Ang-510 strongly inhibited the outgrowth of capillaries
after pre-treatment of the bone explants, suggesting that this agent possess an irre-
versible cytotoxic mode of action on endothelial precursor cells. This observation is in
line with findings of Ahmed et al. and Iyer et al. who showed that the combretastatin
analog A4 phosphate (CA4P) was cytotoxic to proliferating HUVECs.6,32
Finally, we studied the effects of the three compounds on newly established vas-
culature. In contrast to their actions on angiogenesis, marimastat and TNP-470
did not affect newly established capillaries. In vitro studies exploring the effects on
established vasculature are very rare, however, in one study, using cultures of rat
aorta, marimastat showed to stabilize rather than to inhibit existing microvessels
and to prevent their regression, resulting in the prolonged survival of microvascular
networks.33 To date, no studies on the effects of TNP-470 on established vasculature
have been published. However, our observations, that this agent has no effect on
established vasculature may be perceivable, since TNP-470 has been shown to act
on endothelial cells via a cytostatic action through suppression of the cell cycle.28
Furthermore, as expected, next to its strong inhibitory effects on angiogenesis and
capillary outgrowth after pre-treatment of bone explants, Ang-510 showed to have a
marked disintegrative effect on newly established vasculature. This damaging effect
of Ang-510 was most likely specific for endothelial cells, as concomitant HE staining
revealed that the underlying layer of fibroblastic cells remained unaffected. In line
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with our findings, the VDA CA4P showed in vitro and in vivo rapid disruption of
the tubulin cytoskeleton and changes in the three-dimensional shape of proliferating
endothelial cells.34–36
In conclusion, the current search for more specific and more active VDAs is ham-
pered by a lack of in vitro models that can accurately distinguish between effects
on angiogenesis and on established vasculature, urging the need for models which
can specifically differentiate between the two. The overlap in action of VDAs on
angiogenesis and on newly established vasculature illustrates the usefulness of this in
vitro model, which is able to differentially recognize effects on both vascular targets.
This in vitro model provides an efficient and rapid way to screen for biological ac-
tivity of anti-vascular compounds, which could prove of great benefit in the field of
vascular research. Moreover, the ability to make a clear distinction between different
vascular targets may facilitate the identification of pharmacological compounds with
potential clinical benefit. The indicated differences between marimastat, TNP-470
and Ang-510 in targeting vascular networks are illustrative for this approach.
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Abstract
It has been estimated that 70% of advanced breast cancer patients will face the
complication of bone metastases. Three processes are pivotal during bone metastatic
growth of breast cancer, namely, tumor cell proliferation, angiogenesis, and osteolysis.
During tumor-induced osteolysis, a number of cytokines and growth factors are re-
leased from the degraded bone matrix. These factors stimulate further tumor growth,
tumor angiogenesis, and tumor-induced osteolysis. New therapies should target all
relevant processes to halt this powerful feedback loop. Here, we characterized the new
2-methoxyestradiol analogue ENMD-1198 and showed that it is cytotoxic to tumor
cells. Moreover, ENMD-1198 showed both anti-angiogenic and vascular disruptive
properties and was capable of protecting the bone against tumor-induced osteolysis.
We confirmed the in vitro data with a series of in vivo experiments showing the
beneficial effects of ENMD-1198 and ENMD-1198 based combination treatments of
metastatic breast cancer in bone both on tumor progression and on survival with long-
term ENMD-1198 treatment. We confirmed the in vivo relevance of the ENMD-1198
protective effect on bone both with X-ray radiographs and micro-computed tomog-
raphy. In addition, we combined ENMD-1198 treatment with low-dose metronomic
cyclophosphamide and the bisphosphonate risedronic acid, leading to a mild increase
in treatment efficacy.
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Introduction
The preference of breast cancer to metastasize to bone followed by growth and bone
destruction involves specific tumorhost interactions. It has been estimated that 70%
of advanced breast cancer patients will face complications of bone metastases, which
includes osteolytic lesions resulting in severe bone pain, fracture, hypercalcemia, and
nerve compression.1–3
Several processes are crucial during bone metastatic growth. These processes
include tumor growth and tumor-stroma interactions such as local pro-angiogenic
signaling, local activation of the innate immune system, and local suppression of the
adaptive immune system.3–6 Regulatory T (Treg) cells are capable of blocking local
immune responses. A local increase in Treg cells is a major factor in the tolerance
and immune avoidance of tumors.7 Pro-angiogenic signaling and the local alterations
of the immune system both have a positive feedback on tumor growth.
In addition, breast cancer cells are capable of releasing parathyroid hormone-
related protein (PTHrP), which activates receptor activator for nuclear factor κ B
ligand (RANKL) on stromal cells and osteoblasts. RANK-RANKL signaling not only
leads to an increase in osteoclastogenesis but also prolongs the lifetime of osteoclasts,
resulting in increased bone resorption. During bone resorption, several growth fac-
tors and cytokines are released from the bone matrix. These include transforming
growth factor-β (TGF-β), insulin like growth factors (IGFs), fibroblast growth fac-
tors (FGF-1 and -2), platelet derived growth factor (PDGF) and bone morphogenic
proteins (BMPs). The released growth factors stimulate tumor cell proliferation
and survival. TGF-β induces the upregulation in vascular endothelial growth factor
(VEGF) expression by tumor cells leading to an increase in tumor angiogenesis.8
Moreover, TGF-β stimulates the production and release of PTHrP by the tumor
cells resulting in a self sustaining feedback loop known as the vicious cycle of bone
metastases.9–12
Because of the complex nature of bone metastasis, new treatments should si-
multaneously target tumor cell proliferation, angiogenesis, immunologic alterations,
and halt the cycle of bone metastases. In this study we describe the in vitro and
in vivo efficacy of a combination therapy targeting these major processes involved
in metastatic growth in bone. To do so, we combined low dose ”metronomic” cy-
clophosphamide (CTX), 2-methoxyestradiol (2ME2, Panzem) derivate ENMD-1198
and the bisphosphonate risedronic acid.
Previous research indicated that the therapeutic effect of metronomic chemo ther-
apy is mainly due to a reduction of tumor angiogenesis rather than direct cytotoxic-
ity.13,14 In addition, metronomic CTX selectively depletes Treg cells resulting in an
enhanced tumor immune response.15,16
The naturally occurring estrogen metabolite 2ME2 (Figure 6.1) has been shown
to have anti-tumor, anti-angiogenic and anti-resorptive effects.17,18 In vivo therapeu-
tic effects of 2ME2 are moderate because of the rapid inactivation via conjugation






















Figure 6.1: 2ME2 and ENMD-1198 structures. (a) Structural formula of the estrogen metabolite
2-methoxyestradiol (2ME2). Rapid inactivation of 2ME2 occurs in vivo via oxidation (at
position 17) or conjugation (positions 3 & 17). (b) The 2ME2 derivate ENMD-1198 has been
altered at positions 3 and 17 resulting in slower inactivation and increased plasma levels of the
active compound in vivo. Both compounds have very low affinity for the estrogen receptor.
with reduced metabolic liabilities (Figure 6.1b).19 It displays anti-proliferative ef-
fects on tumor cells and neo-angiogenesis very similar to 2ME2. ENMD-1198 inhibits
pro-angiogenic signaling through downregulating hypoxia-inducible factor 1α (HIF-
1α) and STAT3 and it has vascular disruptive effects.20–22 To date, no studies on
treatment of bone metastases or bone specific effects with ENMD-1198 have been
published. ENMD-1198 is currently in clinical trial for treatment of primary breast
cancer.23
Bisphosphonate treatment blocks osteoclast function, thereby halting the cycle of
bone metastatic growth.24–26 It has been shown in vivo that bisphosphonate treat-
ment mainly prevents the development of new metastases while exhibiting a tran-
sient effect on already established metastases.27 Also, bisphosphonates reduce skeletal
complications and morbidity in patients with bone metastases.28
The combination treatment of metronomic CTX, bisphosphonates, and ENMD-
1198 targets all of the aforementioned major processes involved in osteolytic bone
metastasis of breast cancer, namely, tumor cell proliferation, angiogenesis, local im-
mune suppression, and osteolysis. By targeting the tumor stroma, in addition to the
cancerous cells, less drug resistance is to be expected over time. The aim of this
study was to assess the efficacy of ENMD-1198 treatment on tumor growth and bone
destruction in a murine model for osteolytic breast cancer metastases and to evaluate
a possible synergy between ENMD-1198, metronomic CTX, and bisphosphonates.
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Materials and Methods
Animals
Pregnant Swiss albino and female athymic mice (BALB/c nu/nu, 46 weeks old) mice
were acquired from Charles River Laboratories, housed in individually ventilated
cages, and food and water were provided ad libitum. All surgical and analytic pro-
cedures were done under isoflurane gas anesthesia. Tumor diameters in the animals
were measured routinely. Animals were sacrificed by cervical dislocation at the end
of the experimental period or when the tumor diameter exceeded 1cm in concordance
with local guidelines for the use of animals in cancer research. Animal experiments
were approved by the local committee for animal health, ethics, and research of
Leiden University Medical Center.
Cell lines and culture conditions
The cell lines MDA-231-B/Luc+ (hereafter MDA-BO2), a bone-seeking and luciferase-
expressing subclone from the human breast cancer MDA-MB-23129,30 cell line, and
RAW264.7, a murine osteoclast precursor cell line (American Type Culture Collec-
tion), were cultured in DMEM (Invitrogen) containing 4.5g glucose/l supplemented
with 10% fetal calf serum (FCS; Lonza), 100 units/ml penicillin, 50µg/ml strepto-
mycin (Invitrogen), and 800µg/ml geneticin/G418 (Invitrogen).
Both cell lines were grown in a humidified incubator at 37◦C and 5% CO2. All
cell lines were monthly checked for Mycoplasma infection by PCR. Cells were checked
routinely for morphologic changes, and no other authentication tests were done on
these cell lines because they were acquired in the laboratory.
In vitro viability assays
Both MDA-BO2 and RAW264.7 were plated in a 96-well plate (Costar) in 100µl
medium at a density of 10,000 cells per well and left over night to adhere. The next
day the medium was replaced with medium containing the experimental compounds,
6 wells per condition. After 24, 48, or 144 hours, cell viability was measured using
a nonradioactive colorimetric MTS viability assay (Promega Benelux) according to
the manufacturer’s protocol. Optical absorption was measured at 490nm with a
Versamax absorbance microplate reader (Molecular Devices).
In vitro vascularization models
In vitro angiogenesis was measured as outgrowth of endothelial capillary structures
from cultures of 17-day old fetal mouse metatarsal bone explants, as described previ-
ously.31 In short, pregnant Swiss albino mice were sacrificed by cervical dislocation at
day 17 of gestation and isolated fetal metatarsals were cultured in α-MEM medium
containing 10% FCS (Lonza), penicillin (100units/ml), and streptomycin (50µg/ml;
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Invitrogen) and left for 48 hours to adhere. Thereafter, the feed was replaced with
medium containing VEGF (50ng/ml; rhVEGF-A; Oncogene Science). After 10 days
of culture, the explants were fixed and stained with ER-MP12 antibody directed
against murine PECAM-1 (CD31; kind gift of Dr. P. Leenen, Erasmus University,
Rotterdam, the Netherlands).
Images were obtained using a digital camera and the area of PECAM-1-positive
tubular structures was quantified by image analysis using ImageJ 1.43r (Wayne Ras-
band, National Institute of Health, USA).
In vitro effects on newly established vasculature were examined as described pre-
viously.32 In short, isolated 17-day old fetal metatarsals were left to adhere and
cultured for 10 days in the presence of VEGF (50ng/ml) to stimulate capillary net-
work formation. Thereafter, the feed, was replaced by medium containing the test
substances. After 24 hours, bone explants were fixed and stained for PECAM-1 for
further analysis as described before.
In vitro bone resorption assay
Bone resorption was assessed as described earlier.33 In short, pregnant Swiss Albino
mice were injected with 30µCi 45Ca (1Ci/mmol; PerkinElmer, Waltham, MA USA)
on day 16 of gestational age. The animals were sacrificed on day 17 and the 45Ca
pre-labeled fetal metatarsals were isolated and pre-cultured in 1ml of α-MEM (Invit-
rogen) supplemented with 0.1% BSA in six well plates (Costar) for 24h. This allowed
45Ca exchange in the bones with the culture medium. The metatarsals were then cul-
tured in 250µl of (α-MEM, 0.1% BSA) in 24-well plates for 10 days in the presence of
100nM PTHrP (1–34) (Bachem, Bubendorf, Switzerland) with or without additives
(n = 6 per condition). Finally, medium was removed and residual 45Ca was extracted
from the bones in 5% trichloroacetic acid for 24h. The amount of 45Ca in both the
culture media and the decalcification fluid was determined by liquid scintillation us-
ing a β-counter (Packard 1600 TR, Groningen, The Netherlands). Resorption was
expressed as percentage of 45Ca from the pre-labeled explants that is released in the
medium during culture (45Ca release (%) =
45Ca in medium (cpm)
total 45Ca (cpm)
· 100%).
In vivo treatment of bone metastases
MDA-BO2 cells were injected into the right tibiae as described previously.30 In brief,
2 holes were drilled through the bone cortex of the upper right tibia with a 25-gauge
needle (25G 5/8; BD Micro-Fine) and bone marrow was flushed out. Subsequently,
250,000 MDA-BO2 cells/10µl PBS was injected into the right tibiae of 6-week-old
nude mice. Three days after intra-osseous inoculation of MDA-BO2 cells, the animals
were randomly divided in groups (n = 10).
In a first experiment, 4 groups of mice (n = 10) received either ENMD-1198
(200mg/kg/day, per oral gavage) or CTX (30mg/kg/day, through the drinking water
as described previously30) or a combination of ENMD-1198 and CTX or vehicle
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control. Treatment started at day 7 after inoculation and was continued throughout
the experiment. After 6 weeks the animals were sacrificed by cervical dislocation
hind-limbs were fixed and kept for ex vivo X-ray analysis.
In a second experiment, 4 groups of mice (n = 10) received ENMD-1198 (200mg/kg/-
day, per oral gavage) or ENMD-1198 + CTX (30mg/kg/day, through the drinking
water) or ENMD-1198 + CTX + Risedronic Acid (Procter & Gamble Pharmaceuti-
cals, Norwich, NY USA) (1.6mol/kg/day, by sub cutaneous injection).
Bioluminescence Imaging
The progression of cancer cell growth was monitored weekly by bioluminescence
imaging (BLI) using the IVIS100 Imaging System (Caliper Life Sciences, Hopkinton,
MA USA).
X-ray radiographs and CT analysis
At the experimental endpoints, mice were sacrificed and the tumor bearing hindlimbs
were removed and assessed for osteolytic lesions by using a Faxitron 43805 (Hewlett
Packard). X-ray radiographs were scanned and subsequently analyzed using Adobe
Photoshop (Adobe Systems, San Jose, CA, USA).
Micro-computed tomographic (µCT) scans were made using a SkyScan 1076 CT
scanner (SkyScan, Kontich, Belgium) using a source voltage set to 40kV and a source
current set to 250µA, with a step size of 0.9◦over a trajectory of 180◦. Images were
taken with a frame average of 3 to reduce noise and an image pixel size of 9.03µm.
Reconstructions were made using nRecon software (SkyScan) with a beam hardening
correction set to 20% and a ring artifact correction set to 5. Volume measurements
and visualizations were performed using MeVisLab (MeVis Medical Solutions AG,
Bremen, Germany).
Statistics
Results are depicted as mean value ± standard error of the mean (SEM). Differ-
ences between groups were determined by one-way analysis of variance for multiple
comparisons followed by student’s t-test for differences between two specific groups.
Results
ENMD-1198 reduces MDA-BO2 cell viability in vitro
The direct effect of the proposed treatment on tumor cells was assessed in vitro.
In order to do this, the effect of ENMD-1198 on cell viability was investigated us-
ing an MTS colorimetric cell viability assay and with drug concentrations ranging
from 0.1µM to 3.2µM. The MTS assay was performed after 48 hours exposure to
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Figure 6.2: ENMD-1198 treatment reduces viability of MDA-BO2 cells in vitro, low dose cy-
clophosphamide does not. (a) ENMD-1198 is reduces MDA-BO2 cell viability. Cell
viability was measured after 48 hours of ENMD-1198 treatment. (b) Low doses of 4-
hydroperoxycyclophosphamide (4-HC) do not reduce MDA-BO2 cell viability. Cell viability
was measured after 24 hours (direct effect) and 144 hours (prolonged metronomic treatment
effect) of 4-HC treatment. 4-HC is the main active metabolite of cyclophosphamide.
ENMD-1198. ENMD-1198 inhibited MDA-BO2 cancer cell viability with an IC50 of
approximately 0.8µM (Figure 6.2a).
The effect of CTX on cell viability was investigated using an MTS colorimetric
cell viability assay and with drug concentrations of the active CTX metabolite Hy-
droxyperoxycyclophosphamide (4-HC), ranging from 1nM to 10µM. The low 4-HC
concentrations up to 0.1µM were similar to concentrations measured in vivo during
metronomic CTX treatment.34 Cell viability was measured after both 24 and 144
hours exposure to 4-HC to assess the effects of direct treatment and prolonged ex-
posure, respectively. Neither short or long term effects of 4-HC treatment could be
observed using drug concentrations up to 0.1µM (Figure 6.2b).
ENMD-1198 has both an anti-angiogenic effect as well as a
vascular disruptive effect in vitro
The vascular effect of ENMD-1198 was assessed in vitro. The anti-angiogenic effect of
ENMD-1198 treatment was investigated using an in vitro fetal metatarsal outgrowth
angiogenesis assay. The fetal metatarsal explants contain a multitude of stromal and
vascular/endothelial precursor cells. This cellular complexity closely mimics the in
vivo situation during angiogenesis.31 Low concentrations of ENMD-1998 slightly en-
hanced the vascular outgrowth suggesting a possible biphasic effect of ENMD-1198
on angiogenesis. However, this enhancement was not statistically significant. Higher
doses of ENMD-1198 had profound dose dependent effects on VEGF stimulated an-
giogenesis (Figure 6.3a-b).
Next, the effect of ENMD-1198 treatment on previously established vasculature
was assessed using metatarsal explants and an optimized vascular disruption protocol
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Figure 6.3: ENMD-1198 has both an anti-angiogenic effect as well as a vascular disruptive
effect in vitro. (a) ENMD-1198 treatment inhibits angiogenesis in a mouse fetal metatarsal
explants angiogenesis assay. Metatarsals were cultured for 10 days in the in the presence
of VEGF and ENMD-1198 as indicated in the graph. After CD31 staining, the cultures
were photographed and the surface area covered by the vascular outgrowth was quantified
using ImageJ. Indicated statistical significant differences are in comparison with the VEGF
treated control (∗p < 0.05; ∗ ∗ ∗p < 0.001). All differences in vascular outgrowth between
the three ENMD-1198 concentrations are statistically significant. (b) Representative images
of the mouse metatarsal angiogenesis assay showing the metatarsal bone surrounded by
vascular outgrowth. (c) ENMD-1198 treatment disrupts pre-existing vasculature in a mouse
fetal metatarsal explants vascular disruption assay. The fetal explants were treated with
ENMD-1198 for 24 hours as depicted in the graph after 10 days of culture in the presence
of VEGF (50ng/ml). After CD31 staining, the cultures were photographed and the surface
area covered by the vasculature was quantified using ImageJ. Indicated statistical significant
differences are in comparison with the untreated control (∗ ∗ p < 0.01; ∗ ∗ ∗p < 0.001).
(d) Representative images of the mouse metatarsal vascular disruption assay. Note the
remaining fragments of endothelial structures indicating areas where the vascular network
has been disrupted.
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Figure 6.4: ENMD-1198 has anti-resorptive effects in vitro. (a) Both 2ME2 and ENMD-1198 reduce
the viability of RAW264.7 cells, an osteoclast precursor cell line. ENMD-1198 had an IC50
of approximately 0.4µM and was shown to be four times more potent than 2ME2 (IC50 ∼
1.6µM). Cell viability was measured after 48 hours of 2ME2 or ENMD-1198 treatment.
Indicated statistical significant differences are in between 2ME2 and ENMD-1198 (∗p <
0.05; ∗ ∗ ∗p < 0.001). (b) ENMD-1198 treatment inhibits bone resorption in a mouse fetal
metatarsal explants 45Ca release assay. Radioactive 45Ca-labeled murine fetal metatarsals
were culture under the conditions depicted in the graph. The ratio of the amount of 45Ca
in the culture medium and the amount of 45Ca in the bone was measured after 10 days of
culture. Indicated statistical significant differences are in comparison with the untreated
control, stimulated with PTHrP. Although the 5µM was not significantly different from the
untreated control, it was different from the lower treatment concentrations (p = 0.006 when
compared to 0.1µM) (∗ ∗ p < 0.01; ∗ ∗ ∗p < 0.001).
as previously described.32 Like the metatarsal angiogenesis assay, this assay contains
a multiple cell complexity making it a relevant assay mimicking the in vivo situation.
The newly established vascular bed in this assay, like tumor vasculature, is immature
and does not contain pericytes. Comparable to the angiogenesis assay, low doses of
ENMD-1198 ENMD-1998 slightly enhanced the vascular outgrowth without statisti-
cal significance. Higher doses of ENMD-1198 disrupted newly established vasculature
with an IC50 of approximately 0.8µM (Figure 6.3c-d).
ENMD-1198 reduces the viability of RAW264.7 osteoclast pre-
cursor cells and inhibits PTHrP stimulated bone resorption
The bone effect of ENMD-1198 was assessed in vitro. The effects of ENMD-1198
and 2ME2 on the viability of RAW264.7 osteoclast precursor cells were investigated
using an MTS colorimetric cell viability assay and with drug concentrations ranging
from 0.1µM to 12.8µM. The MTS assay was performed after 48 hours of ENMD-1198
or 2ME2 exposure. Both ENMD-1198 and 2ME2 reduced RAW264.7 cell viability.
With an IC50 of approximately 0.4µM, ENMD-1198 was four times more potent than
2ME2 (IC50 ∼ 1.6µM) (Figure 6.4a).
After investigating the effects of ENMD-1198 on osteoclast precursor cells, a
45Ca release assay was performed to investigate whether ENMD-1198 could effec-
tively block PTHrP stimulated bone resorption. The assay was conducted using
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45Ca-labeled fetal mouse metatarsals in serum free medium with 0.5% BSA. Bone
resorption was stimulated by addition of 100nM PTHrP to the culture medium. This
culture condition is especially suitable to study effects on PTHrP induced bone re-
sorption.33 ENMD-1198 effectively blocks PTHrP stimulated 45Ca release in a dose
dependent manner (Figure 6.4b).
ENMD-1198 based combination treatments inhibit tumor growth
in vivo
Following the in vitro characterization of ENMD-1198 on the three major processes
involved in skeletal metastatic growth of breast cancer, the ENMD-1198 based com-
bination treatment effects were assessed in vivo. To investigate the effect on tumor
burden, mice were treated either with ENMD-1198, CTX or ENMD-1198 + CTX.
Tumor growth was followed using BLI. In all treated groups the tumor burden was
decreased significantly compared to the untreated controls by day 27. There was
a trend that ENMD-1198 treatment was more effective than CTX alone. A differ-
ence between ENMD-1198 and the ENMD-1198 + CTX combination could not be
observed (Figure 6.5a).
Next we wanted to investigate whether adding a bisphosphonate (risedronic acid)
to the ENMD-1198 + CTX combination would improve the treatment outcome.
The ENMD-1198 + CTX treated group had a significantly reduced tumor burden
compared to the control by day 21. There was a trend that the ENMD-1198 and the
ENMD-1198 + CTX + risedronic acid treated groups had a reduced tumor burden
as well. The animals in the control group were sacrificed before these differences
could reach significance because the tumor size in the control group exceeded 1cm in
diameter, a defined endpoint stated in the Dutch guidelines for animal experiments in
cancer research. However, differences in growth kinetics between the treated groups
and the untreated group can still be appreciated. The tumor development in this
experiment was more rapid than in the previous experiment. In conclusion, adding
risedronic acid to the treatment did not improve treatment outcome (Figure 6.5b).
ENMD-1198 based combination treatments are capable to con-
trol tumor growth, but are unable to eradicate the tumor
After investigating the treatment effects on tumor burden, the efficacy of long term
treatment with ENMD-1198 or ENMD-1198 based combinations was assessed. Seven
days after intra-osseous inoculation with MDA-BO2 cells, mice were treated with
either ENMD-1198, ENMD-1198 + CTX, ENMD-1198 + risedronic acid, ENMD-
1198 + CTX + risedronic acid or vehicle control. The treatment continued for a
maximum of ten weeks. In accordance to the Dutch guidelines for animal experiments
in cancer research, mice were sacrificed when the tumor diameter exceeded 1cm.
All three ENMD-1198 based combination treatments were able to control tumor
growth over a prolonged period of time. The animals receiving the combination
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Figure 6.5: ENMD-1198 based combination treatments reduce tumor burden, but does not
eradicate the tumor. (a) Treatment started 7 days after inoculation (T0). All treated
groups had a reduced tumor burden compared to the untreated control (∗p < 0.05). There
was a trend that the ENMD-1198 treated group had a lower tumor burden compared to
the CTX treated group (p = 0.063). (b) The ENMD-1198 + CTX combination group had
a statistically significant decreased tumor burden compared to the control group at day
21 (p = 0.026). There was a trend that the ENMD-1198 and the ENMD-1198 + CTX
+ risedronic acid treated groups had a reduced tumor burden compared to the untreated
controls (p = 0.088 and p = 0.086 respectively). However, the control mice died before this
difference could reach significance. (c) Survival curves of mice treated with ENMD-1198
based combinations. Mice were inoculated intra-osseous with MDA-BO2 cells. Treatment
started 7 days after inoculation (T0). Mice were sacrificed when the tumor exceeded 1cm
diameter in accordance with local guidelines. Treatment was stopped after 10 weeks. One
mouse in the ENMD-1198 treated group died in week 4 due to an accident with the oral
gavage. The tumor size reached a steady state in the treated groups during the treatment
period, but rapidly expanded after the treatment was stopped. (d–f) Individual graphs for
each of the combination treatments. ENMD-1198 versus control (d). ENMD-1198 + CTX
versus control (e). ENMD-1198 + CTX + risedronic acid versus control (f).
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of ENMD-1198 and risedronic acid appeared less healthy with a thinner skin and
aberrant behavior, suggesting possible adverse effects of long term treatment with
this combination of drugs. The tumors grew exponentially as soon as the treatment
was stopped after ten weeks. The addition of low-dose CTX and/or risedronic acid
did not improve treatment outcome (Figure 6.5c-f).
ENMD-1198 protects the bone against tumor-induced osteoly-
sis in vivo
Finally, the effect of ENDM-1198 treatment on tumor induced osteolysis was as-
sessed using both X-ray radiographs and high resolution µCTscans made ex vivo
after sacrificing the mice. These include untreated controls and groups treated with
ENMD-1198 or CTX or a combination of ENMD-1198 + CTX. The corresponding
BLI data of these animals are depicted in Figure 6.5a. In the X-ray radiographs, the
surface area of osteolytic lesions was measured after manually drawing a region of
interest around the lesion. The osteolytic lesions were significantly smaller in groups
which received ENMD-1198 than the groups which did not receive ENMD-1198 (Fig-
ure 6.6a).
Because the radiograph method is based on a manual definition of the osteolytic
lesion we wanted to confirm these results in using a method that is less susceptible
to bias. To do so, the bone volumes of the upper half of the tibiae of these mice were
measured in µCTscans. The groups which received ENMD-1198 had a significantly
larger bone volume than the groups which did not receive ENMD-1198, confirming
the X-ray radiograph data (Figure 6.6b).
Discussion
This study was the first to assess the treatment efficacy of the 2ME2 derived com-
pound ENMD-1198 on osteolytic bone metastasis of breast cancer. Our results in-
dicate that ENMD-1198 interferes with all the crucial processes of bone metastatic
growth of breast cancer namely, tumor cell proliferation, angiogenesis and bone re-
sorption. We confirmed our in vitro data with a series of in vivo experiments showing
the beneficial effects of ENMD-1198 and ENMD-1198 based combination treatments
of metastatic breast cancer in bone both on tumor progression and survival with
long term treatment over a period of 10 weeks. Furthermore, we showed the in vivo
relevance of the ENMD-1198 protective effect on bone.
The observed in vitro effects of ENMD-1198 on cell viability were in line with
earlier findings.19 ENMD-1198 and 2ME2 are microtubule disrupting agents. Similar
to other microtubule disrupting agents, they interfere with cell mitosis and thus have
profound anti-proliferative effects on tumor cells and during neo-angiogenesis while
resting cells are unaffected. Moreover, 2ME2 causes the phosphorylation of Bcl-2 and
Bcl-xL leading to an upregulation of the intrinsic and extrinsic apoptotic pathways,
a mechanism shared with paclitaxel.35
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Figure 6.6: ENMD-1198 treatment protects the bone against tumor-induced osteolysis in vivo.
(a) Quantification of osteolytic lesion size by surface measurement on X-ray radiographs. X-
ray radiographs were made after termination of the experiment. The lesion surface was
measured in number of pixels. Graphs show the average and standard error of the mean.
Groups treated with ENMD-1198 have smaller lesions than the other groups (∗ ∗ p < 0.01;
∗∗∗p < 0.001). (b) Quantification of osteolytic lesion size volume measurement in µCTscans.
µCTscans were made after termination of the experiment. Bone volumes of the upper half
of the tibia (region of interest is indicated in the inset), cut-off planes were always defined
in a 90◦ degree angle to the bone. Graphs show the average and standard error of the mean.
Groups treated with ENMD-1198 had a larger bone volume than the other groups confirming
the radiograph data (∗p < 0.05; ∗ ∗ p < 0.01). (c) Representative X-ray and µCTimages
of all the treatment groups. Both X-ray and µCTanalysis show a reduction in osteolysis in
ENMD-1198 treated groups.
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ENMD-1198 and 2ME2 reduce angiogenesis by inhibiting the expression and nu-
clear accumulation of HIF-1. This results in a down regulation of VEGF expression
and local pro-angiogenic signaling.21,22,36,37 This impaired hypoxia sensing increases
local concentrations of radical oxygen spiecies enhancing the pro-apoptotic effects of
these compounds.21,22 In addition, ENMD-1198 interferes with endothelial cell motil-
ity, chemotaxis and morphogenesis into capillary-like structures.22 The results of our
in vitro angiogenesis assay and vascular disruption assay confirmed these findings.
Metronomic CTX inhibits angiogenesis via three different mechanisms; by direct
induction of apoptosis of proliferating tumor endothelial cells, by blocking or reducing
the viability of circulating endothelial progenitor cells (EPCs) and by elevating levels
of cellular and circulating thrombospondin-1 (TSP-1). These anti-angiogenic effects
are enhanced in combination with VEGF inhibitors.13,14 Our finding that in vitro
treatment with 4-HC is not cytotoxic to breast cancer cells were in line with earlier
experiments conducted by Bocci et al.13
We expected to find a strong synergy between the anti-angiogenic effects of
ENMD-1198 and metronomic CTX treatments in vivo since both treatments have
been reported to inhibit angiogenesis via different mechanisms. The CTX + ENMD-
1198 combination resulted in a better treatment outcome than CTX treatment alone,
but this difference was not profound enough to suggest any synergy between CTX
and ENMD-1198. Moreover, adding CTX to ENMD-1198 treatment did improve the
overall outcome compared to ENMD-1198 alone in one in vivo experiment, but did
not in the other.
ENMD-1198 reduced osteoclast precursor cell viability and was able to inhibit
PTHrP stimulated bone resorption in vitro. When comparing the CTX treated
group and the ENMD-1198 treated groups, there was a significant 60% reduction in
osteolytic lesion size in the ENMD-1198 treated groups. The differences in tumor
burden were much smaller and not significant between all groups. CTX treatment
did not improve the osteolytic phenotype compared to the control group even though
the tumor burden was significantly lower. Taken together, we conclude a strong bone
specific effect of ENMD-1198 treatment.
To date, this is the first study showing these bone-specific effects of ENMD-1198.
It has previously been shown that 2ME2 inhibits osteoclast differentiation and bone
resorption and is cytotoxic to osteoclasts.38 Interestingly, a 2ME2-mediated upregu-
lation of osteoprotegerin has been described in osteosarcoma cells. This induction of
osteoprotegerin can contribute to the anti-resorptive functions of 2ME2 in osteolytic
metastatic lesions.39,40 Induction of osteoprotegerin might be part of the mechanism
in which ENMD-1198 protects the bone matrix from degeneration. The addition of
risedronic acid to the combination treatment did not have an effect on tumor growth,
nor did it prolong the survival of the animals.
In conclusion, ENMD-1198 treatment of osteolytic bone metastases has profound
in vivo effects on both tumor growth and osteolysis. ENMD-1198 based combina-
tion treatments can control tumor growth; however, the tumor continues growing
after treatment is stopped indicating a strong cytostatic effect. Due to the potent
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cytostatic and anti-angiogenic effects of ENMD-1198, only a weak additional value
of having CTX treatment could be observed. However, any additional value of CTX
treatment might be stronger in an immune competent model due to a selective de-
pletion of Treg cells.
41 ENMD-1198 has strong anti-resorptive properties and the
addition of risedronic acid to the treatment did not improve the overall treatment
outcome. ENMD-1198 is a promising new compound in the field of metastatic bone
disease affecting all processes that are crucial during development and growth of bone
metastases.
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Summary & Conclusions
Bone metastatic growth is characterized by tumor-induced bone resorption and sub-
sequent tumor stimulation by factors released from the resorbed bone matrix. This
feedback mechanism is known as the vicious cycle of bone metastases.
The complex interaction between bone metastases and the bone micro-environment
requires a treatment interfering with multiple pathways. Bone resorption is an at-
tractive treatment target to halt the vicious cycle of bone metastases. This, can be
targeted alongside other processes such as tumor cell proliferation and survival, an-
giogenesis and immune modulation. Angiogenesis can be slowed down by inhibiting
VEGF signaling and preventing the recruitment of circulating endothelial precursor
cells (CEPs). The immune system could potentially be activated by targeting regula-
tory T-cells (Treg). Transforming growth factor-β (TGF-β) is released and activated
during bone resorption. Thus, TGF-β stimulation of the tumor can be stopped by
inhibiting osteolysis. The inhibition of osteolysis can either be achieved by direct
targeting of osteoclasts activity or by blocking osteoclast differentiation. Decreased
levels of TGF-β will lead to a decrease in secretion of pro-osteolytic factors, such as
parathyroid hormone-related protein (PTHrP) and macrophage colony-stimulating
factor (M-CSF), by the tumor cells. In addition, the tumor will be left more suscep-
tible to apoptosis. Evaluating the treatment result of such a combined intervention
in a multi-factorial disease process requires simultaneous measurement and follow up
of multiple processes.
Due to their non-invasive nature, whole body molecular imaging techniques are
especially suitable for longitudinal studies. Imaging technique are unique tools. They
enable the quantification of structural changes and disease related processes such as
angiogenesis and tumor growth in a non-invasive manner and at multiple time points.
Altogether, molecular imaging provides the researcher the possibility of evaluating
the result of a therapeutic intervention in over time in the same animal.1–3
Radiography and optical imaging techniques are primarily two dimensional (2D).
However, recent advances have resulted in fluorescence molecular tomography (FMT)
and other three dimensional (3D) fluorescence and bioluminescence data capturing
methods as well as specialized small animal micro-CT (µCT) scanners.1,3–5 The tran-
sition from 2D to 3D results in more realistic data and possibly betters quantification.
However, the navigation through 3D datasets is less intuitive than 2D datasets. More-
over, the determination of a volume of interest (VOI) is more complicated than the
selection of a two dimensional region of interest (ROI).6
Chapter 2 of this thesis describes a method to generate normalized cross-sections
and select VOIs in complex data. The method is based on the definition of a cen-
terline through a long-bone of interest. The naturally curved centerline can then be
“straightened” to generate a new, normalized volume. This new volume can then be
used to extract normalized cross-sections or to define a normalized VOI. The actual
measurement of the selected volume is performed in the original volume to prevent
measurement artifacts due to the straightening procedure. Following this method,
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VOIs are defined relative to the anatomy of the bone.6
An automated method has been developed in-house to follow longitudinal studies
both qualitatively and quantitatively. This method, described in chapter 3, is based
in part on a previously published method to fit an animal atlas over µCT scan
data.7,8 Subsequently, a predefined VOI can be segmented and measured. These
volume measurements are performed fully automated. The acquired data does not
differ significantly from manual segmentation and measurements.9
Using a center-line-based approach, sub-volume datasets of long-bones can be
transformed into a stack of slices cutting through the bone under a 90◦ angle (Chap-
ter 2).6 A similar approach has been implemented in the automated method, but
instead of defining a center-line per scan, the center-line of the segmented atlas bone
is used. The thickness of the bone cortex can be determined in these orthogonal
slices. All the cortical thickness data of the bone of interest can then be projected
as color code on a volume rendering of the bone. This method of generating cortical
thickness maps, described in chapter 3 is a valuable tool to study changes in the
bone anatomy over time. The user of this method can identify the location of osteo-
lytic and osteosclerostic regions.9 This helps in defining regions of interest for further
analysis of the acquired imaging datasets or for subsequent histological examination.
µCT gives a detailed insight in structural changes during the course of a disease
and/or treatment. More insight into the direct molecular and mechanistic response
can be acquired by combining structural imaging modalities with functional imag-
ing. It is not only possible to acquire 3D optical data, but also to project these
3D optical data sets back onto scans of various other modalities (e.g. µCT, PET,
SPECT and MRI). Combining multiple imaging modalities within one study offers
unique research opportunities, but it also lies at the core of the major challenges in
data analysis. Datasets are acquired using various highly specialized cameras and
machines. Each one of these machines often have specific requirements in terms of
anesthetics and animal positioning and produce data in various formats. Animal
handling and moving animals from one machine to another introduce variations in
animal posture between datasets. Most of these posture variations can be prevented
by performing these actions with care. However, the posture variations are even more
abundant in longitudinal studies where animals are imaged at multiple time points,
often with intervals of several weeks. In these cases, specialized animal holders have
proven to be insufficient. Also, during longer studies, for example five or six weeks,
growth of the animal between scans becomes a problem.
Chapters 2 and 3 show how posture variation can be normalized in µCT scans.
In chapter 4 an approach to integrated data handling has been described which uses
the skeleton as a reference frame in order to compensate for posture variations in
datasets acquired with other modalities. This approach is based on the registration
and segmentation of µCT data. In this case 3D optical or nuclear imaging data
(positron emission tomography (PET) and single photon emission computed tomog-
raphy (SPECT)) is coupled to the µCT data and segmented alongside. Also the
handling of MRI data is currently dependent on µCT, but this could be improved in
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future since magnetic resonance imaging (MRI) provides skeletal contrast in addition
to soft tissue contrast.
A great number of in vitro assays are available which are used to evaluate the
effect of possible new treatments in a laboratory setting. There are many different
ways to assess the anti-angiogenic capabilities of a compound. These assays include
proliferation assays of human umbilical vein endothelial cells (HUVECs) and tube
forming assays in three dimensional culture systems. Most of these in vitro models
for angiogenesis include only one cell type, namely endothelial cells. However, angio-
genesis is a complex process in which multiple cell types interact. Moreover, existing
assays focus on quantifying the effect of compounds on vascular outgrowth and the
formation of new vessels. The vascular disruption capability of a new compound is
often not quantified.
A new vascular disruption assay is described in chapter 5. This assay is a vari-
ation to an angiogenesis assay developed within the LUMC by Deckers et al.10 The
angiogenesis and vascular disruption assay are unique in the sense that they consist
of ex vivo bone explants containing all cell types involved in vasculogenesis. The
newly formed vascular bed in these assays is a model for tumor vasculature which,
much like the vessels in these assays, is poorly matured and often lacks support by
pericytes and smooth muscle tissue.10 The vascular disruption assay described in
this thesis is the first multicellular assay which can be used to quantify treatment
responses on newly established vasculature.11
The in vitro angiogenesis and vascular disruption assays and the methods of
analyzing µCT scans have been used in chapter 6 for evaluation of the treatment
effect of a combination treatment for bone metastases. The rationale behind the
treatment design was to simultaneously target all the important processes during
metastatic growth in bone, namely tumor growth, angiogenesis and bone resorption.
The treatment consisted of ENMD-1198 (a 2-Methoxyestradiol (2ME2) derivate),
low dose “metronomic” cycplophosphamide and the bisphosphonate risedronate.
2ME2 is a a microtubule targeting agent (MTA). As such 2ME2 has anti-proliferative
effects against fast dividing cells such as cancerous cells and developing endothelial
cells during angiogenesis.12–15 Moreover, 2ME2 causes the phosphorylation of Bcl-
2 and Bcl-xL, leading to an upregulation of the intrinsic and extrinsic apoptotic
pathways, a mechanism shared with paclitaxel.16
The anti-angiogenic effects of 2ME2 are not solely caused by its cytotoxicity
towards endothelial cells. It also inhibits hypoxia-inducible factor-1α (HIF-1α) ex-
pression.17,18 HIF-1α is a pro-angiogenic factor regulating over 70 genes involved
in many cancer related processes like angiogenesis, glycolysis, metastasis and cell
growth, amongst which VEGF.19,20
Furthermore 2ME2 inhibited intra-osseous growth of 4T1 and MDA-MB-231
breast cancer cells and protects the bone from subsequent cancer-induced osteol-
ysis.21,22 This protective effect of 2ME2 on bone is not only a result of a reduced
tumor burden. 2ME2 is also capable of suppressesing osteoclast differentiation and
induces apoptosis of mature osteoclasts.23 Moreover, 2ME2 effectively represses bone
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loss in an animal model of post-menopausal osteoporosis24 and it preserved bone and
reduced the frequency and severity of arthritis in a model of postmenopausal rheuma-
toid arthritis.25
Chapter 6 describes a study where the 2ME2 derived compound ENMD-1198 was
used to treat bone metastatic growth following intra-osseous inoculation with MDA-
BO2 cells, a bone specific subclone of the MDA-MB-231 breast cancer cell line.26
ENMD-1198 is a slightly modified form of 2ME2 which has better characteristics
in terms of metabolic stability, anti-angiogenic activity and cytotoxicity.27,28 We
showed that ENMD-1198 has direct effects on tumor growth, angiogenesis and bone
turnover.29
ENMD-1198 treatment was combined with low dose “metronomic” Cyclophos-
phamide (CTX) in order to improve the anti-angiogenic and anti-vasculogenic effects
of the treatment. CTX is a cytostatic drug which is often in combination with
other anti-neoplastic drugs to treat malignant lymphomas at the maximum toler-
ated dose. It is also used as adjuvant therapy in metastasized ovarian, breast and
prostate cancers. CTX is not cytotoxic in its original form but requires activation
by P450 metabolism in the liver.30,31 Metabolism results in the active metabolite 4-
Hydroxyperoxycyclophosphamide (4HC).32 The low dose used in this study has been
proposed as anti-angiogenic therapy rather than inducing direct tumor cell death.
It has already been shown that cytotoxic agents can have anti-angiogenic prop-
erties at low dose. In 1986, Polverini and Novak were the first to show this with low
dosing of mitoxantrone and bisantrene, two cytotoxic agents which were in clinical
trial at the time.33 A dose dependent inhibition of angiogenesis was found using a
vascularization model of the rat cornea. Interestingly, the authors explicitly note that
there was no untoward toxicity to the tissue at the drug concentrations used in the
experiment. There are three suggested mechanisms underlying the antiangiogenic ef-
fect of metronomic chemotherapy using CTX. First, by directly inducing apoptosis of
proliferating tumor endothelial cells.34 Secondly, by blocking or reducing the viability
of circulating endothelial progenitor cells (EPCs).35 Thirdly, by elevating the levels
of cellular and circulating thrombospondin-1 (TSP-1).36 The anti-angiogenic effect
of metronomic chemotherapy seems to be much stronger in combination with anti-
angiogenic compounds such as VEGF inhibitors.37 In addition to the anti-angiogenic
effects, metronomic cyclophosphamide causes a selective depletion of Tregcells result-
ing in an enhanced tumor immune response.38,39 Low dose CTX has no, or very low,
effect on tissues that are otherwise highly sensitive to maximum tolerated dose CTX
treatment.40
Both ENMD-1198 and metronomic CTX target angiogenesis and tumor vascula-
ture. The main mechanism of ENMD-1198 is to render the tumor cells irresponsive to
hypoxia by interfering with HIF-1α signalling; thus down-regulating VEGF expres-
sion.27 On the other hand, the antiangiogenic effect of metronomic CTX is largely
VEGF independent. It targets endothelial cells of tumor vasculature and vascular
repair by circulating endothelial cells. The fact that these mechanisms of action are
independent suggest a possible synergy between these compounds in combination
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treatment. The date presented in chapter 6 however, showed only a mild benefit of
combined treatment compared to ENMD-1198 treatment alone. The ENMD-1198
treatment alone was very effective leaving only little room for improvement. More-
over, the experiments were performed in an immune deficient model while part or
the low dose CTX treatment effect works through alterations of the local immune
system. This results in suboptimal treatment effects in the chosen model.29
In order to halt the vicious cycle of bone destruction, the treatment was combined
with bisphosphonates (BPs). BPs are widely used in the clinic for the management
of osteoporosis, metastatic bone disease and Paget’s disease ever since patient with
myositis ossificans was treated with BPs, called diphosphonates at the time, for the
first time in 1969.41–44
BP treatment halts the cycle of bone metastatic growth by blocking osteoclast
function.45 BP treatment reduces skeletal complications and morbidity in patients
with bone metastases, but it is not curative.46 In vivo evidence suggests that BPs
can prevent the development of new metastases. However, established metastases
remain largely unaffected by BP treatment.47 A possible explanation for this lies
within the vicious cycle which promotes osteolytic bone metastatic growth. The
positive feedback within this cycle is so strong that the cancer induced osteolysis
becomes practically irresponsive to treatment.
Recent studies suggest that zoledronate treatment stimulates an anti-tumor im-
mune response.48–50 The immune activation of zolendronate is currently studied in
phase I and II clinical trials.48,51,52 Also, several studies indicate direct cytotoxic
and anti-proliferative effects of BPs towards tumor cells.53–55 The actual clinical rel-
evance of these studies remains unclear as these studies are often performed with
very high BP concentrations.56
Risedronate was added to the ENMD-1198 based combination therapy. It was
postulated that, in a combination, BP and ENMD-1198 may be able to stop local os-
teolysis altogether. The results presented in chapter 6 were less optimistic. Adding a
bisphosphonate to the mixture did not result in improved treatment efficacy. In addi-
tion, potentially adverse effects were observed in the animals receiving a combination
of ENMD-1198, CTX and BPs.29 Future work should be aimed at optimizing the
dose of the individual treatments. Moreover, the role of a possible immune compo-
nent should be investigated using tumor models suitable for immunological research.
Chapter 6 is, apart from its biological significance, an example of how tools like those
described in chapter 2, can facilitate research.
Taken together, this thesis describes methods to measure structural changes in the
skeleton using µCT resulting in normalized qualitative and quantitative assessment of
bone volume and thickness. In addition, normalized cross sections can be generated
to allow side-by-side comparison of scan data. It has been shown that these methods
can be used to identify biologically relevant changes. In addition, ENMD-1198 was
identified as a promising compound for the treatment of bone metastases.
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Future Perspective
Molecular imaging and image analysis are fast developing fields. Constant techno-
logical advances result in many new exciting tools and possibilities, but also new
challenges to overcome. Much of the published work in the field of image analysis
has been generated with custom made source codes and scripts. The translation
into more user friendly interfaces often lacks behind. This is unfortunate because
many good solutions to excisting problems stay unnoticed for people using imaging
techniques as research tool as these people themselves are often not experts in image
analysis. It is therefore important that more user friendly interfaces are developed.
One of the exciting aspects of the field of molecular imaging is the fact that these
techniques are at the crossroads of pre-clinical and clinical practice and of diagnosis
and treatment. Many of the image analysis techniques, both described in this thesis
and in other publications, can potentially be used for clinical purposes as well. The
reverse, where clinical applications can be used to solve pre-clinical problems, is often
true as well. The use of a kinetic atlas to segment datasets and visualize changes
over time is not yet used in the clinic. However, radiologists are positive to the idea
of developing this approach for clinical applications.
Optical imaging modalities are becoming more important in diagnosis and treat-
ment. Fluorescence imaging is already being used in operation theaters for sentinel
lymph-node procedures. Also, peri-operative use of topically applied tumor spe-
cific probes on excised tissue is under clinical evaluation. Optical mammography is
under clinical evaluation as a method of monitoring early treatment response to neo-
adjuvant therapy. Further development of clinically approved cancer specific probes
could have a great impact on this field, in the operation theatre, for diagnosis and
during patient follow up.
Currently, methods of aligning partial and whole body clinical CT and MRI data
are being developed within the LUMC department of radiology. The basic principles
of these techniques have their origin in the atlas based approaches developed for
pre-clinical image processing.
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Dit proefschrift beschrijft een aantal methodes om structurele veranderingen in het
skelet te kwantificeren en het verloop van deze veranderingen door de tijd te vol-
gen. Daarnaast worden er methodes beschreven die gebruikt kunnen worden voor de
kwalitatieve beoordeling van botdikte en structurele afwijkingen van het bot. Ook
wordt er een in vitro methode beschreven waarmee de eventuele effecten van stoffen
op nieuw gevormde bloedvaten kan worden gemeten. De relevantie van een aan-
tal van deze methodes wordt aangetoond door deze met succes te gebruiken in een
preklinische studie naar de effecten van verschillende combinatiebehandelingen van
botmetastasen van borstkanker. Een van de hoofdconclusies van deze studie is dat
de stof ENMD-1198 een veelbelovende stof is voor de behandelingen van dit soort
metastasen.
Sommige soorten kanker, met name die van de borst en de prostaat, zaaien bij
voorkeur uit naar botweefsel. In het bot leiden deze zogenaamde botmetastasen tot
een zeer specifiek ziektebeeld dat wordt gekenmerkt door ongecontroleerde botaf-
braak of juist overvloedige botaanmaak. De botmetastasen van borstkanker die in
dit proefschrift aan de orde komen geven over het algemeen metastasen die de botaf-
braak sterk stimuleren.
De verhoogde botafbraak rondom botmetastasen komt doordat de tumorcellen
botafbraak-stimulerende signaalmoleculen produceren en uitscheiden. Uit het afge-
broken bot zelf komen vervolgens ook aantal stoffen vrij. Sommige van deze vrij-
gekomen stoffen stimuleren op hun beurt de tumorcellen tot groeien en tot verdere
productie van botafbraak stimulerende moleculen. Op deze manier ontstaat er lokaal
rond de botmetastase een vicieuze cirkel van signalen gericht op tumorgroei en botaf-
braak.
Een behandeling van botmetastasen is idealiter gericht tegen botafbraak, tegen de
groei en overleving van tumorcellen, tegen de uitgroei van bestaande en vorming van
nieuwe bloedvaten en vóór de activering van het immuunsysteem in een specifieke
respons tegen de tumor. Omdat het hier gaat om zeer uiteenlopende processen is
een behandeling met één stof als “magic bullet” waarschijnlijk niet haalbaar en is
het noodzakelijk op zoek te gaan naar een combinatie van stoffen die gezamenlijk de
gewenste behandeling vormen.
De vicieuze cirkel van botafbraak kan worden doorbroken door het geven van
bisfosfonaten, een klasse moleculen die de botafbraak stil leggen. Daarnaast kan
door, onder andere, het blokkeren van de vasculaire endotheliale groei factor kan
ook de vorming van nieuwe bloedvaten worden afgeremd. Dit effect kan nog eens
worden versterkt door het voorkomen dat endotheliale voorlopercellen, een celtype
dat betrokken is bij het herstel van bestaande en vorming van nieuwe bloedvaten,
door de tumor worden aangetrokken. Het immuunsysteem kan onder andere worden
geactiveerd door bijvoorbeeld de immuunrespons onderdrukkende regulatorische T-
cellen te inactiveren. Om het resultaat van een dergelijke combinatiebehandeling te
kunnen volgen tijdens een preklinische studie zijn er meetmethodes nodig waarmee
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het verloop van verschillende processen, zoals tumorgroei, angiogenese en botafbraak,
door de tijd en tegelijkertijd gevolgd kunnen worden.
Moleculaire beeldvormende technieken zijn geschikt voor het verrichten van kwan-
titatieve en kwalitatieve bepalingen van relevante factoren in preklinische dierstudies.
Deze technieken zijn veelal niet invasief. Dat betekent dat metingen meerdere mo-
menten tijdens het verloop van een experiment kunnen worden uitgevoerd worden op
een levend dier zonder dat het dier daarbij wordt opengemaakt of gedood. Daardoor
is het mogelijk om met deze technieken structurele veranderingen in het skelet en an-
dere ziekte gerelateerde processen zoals bloedvatgroei en tumorgroei te kwantificeren
en het verloop daarvan door de tijd, in één en hetzelfde dier te volgen.
Röntgenfoto’s en opnames gemaakt met optische beeldvormende technieken, zoals
fluorescentie- en bioluminescentieopnames, zijn in principe tweedimensionaal. Tegen-
woordig is het ook mogelijk om met deze technieken driedimensionale opnames te
maken. Een driedimensionale Röntgenfoto is beter bekend als computed tomografie
(CT). Driedimensionale technieken hebben een aantal voordelen ten opzichte van
tweedimensionale technieken, zo geven driedimensionale technieken een realistischer
weergave van de werkelijkheid en betere mogelijkheden tot kwantificering. Het is
echter lastig en tijdrovend om driedimensionale datasets te analyseren. Het is bijvoor-
beeld moeilijk om in een driedimensionale dataset een gestandaardiseerd deelvolume
te selecteren.
Hoofdstuk 2 van dit proefschrift beschrijft een methode om in CT scans deelvolu-
mes te selecteren en weergaves van doorsneden van botten te genereren. De methode
maakt gebruik van een nieuwe, genormaliseerde, ruimte die gegenereerd is uit de scan
data door het bot van interesse recht te maken en het zo te roteren dat het bot parallel
loopt aan de z-as. Deze nieuwe ruimte wordt gegenereerd op basis van een handmatig
gedefinieerde middellijn van het bot. Vervolgens wordt de nieuwe ruimte gecreëerd
die geheel bestaat uit doorsneden onder een hoek van 90◦ ten opzichte van de middel-
lijn. Deze nieuwe ruimte kan dan worden gebruikt voor het genereren van weergaven
van genormaliseerde doorsneden van het betreffende bot of voor het definiëren van
deelvolumes van een bot. Eventuele volumemetingen worden uitgevoerd in de orig-
inele scandataset, nadat het geselecteerde deelvolume uit de genormaliseerde data is
terug geprojecteerd in de originele scandataset, dit om meetfouten als gevolg van de
databewerking te voorkomen.
Een van de problemen met longitudinale studies, waarbij een dier op verschil-
lende momenten tijdens een studie gescand wordt, is dat iedere scan gemaakt wordt
terwijl het dier in en andere houding in de scanner ligt. Hoofdstuk 3 beschrijft een
geautomatiseerde methode om CT data uit longitudinale studies zowel kwalitatief
als kwantitatief te analyseren. Deze methode maakt onder andere gebruik van een
eerder gepubliceerde methode om te compenseren voor variaties in houding waarin
een het dier op verschillende momenten is gescand. Deze variaties worden gecom-
penseerd door een muisatlas over het skelet van het dier in de scandataset te passen.
Vervolgens wordt het skelet in de scan op basis van de atlas opgedeeld in deelvolu-
mes en in een genormaliseerde houding gebracht. Hoofdstuk 3 beschrijft hoe binnen
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deze deelvolumes een vooraf bepaald botdeel automatisch kan worden geselecteerd
en hoe het volume van dit botdeel vervolgens automatisch gemeten kan worden. De
meetresultaten van deze geautomatiseerde methode wijken niet significant af van
meetresultaten die handmatig zijn verkregen volgens de methode uit hoofdstuk 2.
In hoofdstuk 3 wordt er ook, net als in hoofdstuk 2 gebruik gemaakt van een mid-
dellijn. In dit geval wordt de middellijn niet handmatig per scan bepaald, maar wordt
een middellijn vanuit de atlas op de scandataset geprojecteerd. In de orthogonale
doorsneden wordt de dikte van het corticale bot gemeten. De gemeten botdikte wordt
als kleur, rood voor dik en blauw voor dun bot, op een driedimensionale reconstruc-
tie van het bot weergegeven. Deze methode om de corticale botdikte overzichtelijk
weer te geven is nuttig om de locatie van osteolytische en osteoslerotische gebieden
in het bot snel en eenvoudig te identificeren. Op die manier kunnen deze weergaven
de onderzoeker helpen bij het vinden van gebieden die interessant zijn om nader te
bestuderen met, bijvoorbeeld, histologische technieken.
CT kan worden gebruikt bij het visualiseren en kwantificeren van structurele ver-
anderingen die als gevolg van een ziekte of een behandeling optreden. Optische
beeldvormende technieken, gebaseerd op fluorescentie en bioluminescentie, geven
juist meer functionele dan structurele informatie. Deze technieken kunnen onder
andere worden gebruikt voor het volgen van tumorgroei of het visualiseren van mole-
culaire interacties en enzymatische activiteit. Om een compleet beeld te krijgen van
alle structurele en functionele veranderingen tijdens een experiment is het dus nodig
om de data van deze verschillende technieken met elkaar te combineren.
Naast CT zijn er een aantal beeldvormende technieken om driedimensionale data
te verkrijgen. Zo zijn er bijvoorbeeld driedimensionale bioluminescentie- en fluores-
centiecameras, PET, SPECT en MRI. Iedere techniek heeft zijn eigen specifieke sterke
en zwakke punten. De combinatie van deze technieken biedt unieke mogelijkheden en
toepassingen binnen het biologische en medisch onderzoek, maar de gecombineerde
analyse van deze zeer uiteenlopende soorten data gaat gepaard met een aantal grote
uitdagingen. Ieder apparaat dat wordt gebruikt om de datasets te verkrijgen komt
met specifieke eisen omtrent anesthesie en positionering van het dier. Dit leidt ertoe
dat het moeilijk is om het dier iedere keer in exact dezelfde houding te scannen. Dit
wordt helemaal onuitvoerbaar als een dier op meerdere momenten tijdens een proef
gescand moet worden. Ook wanneer er speciaal ontwikkelde houders gebruikt worden
waar het dier in kan worden gelegd blijken er toch nog verschillen in houding aan te
zijn.
De hoofdstukken 2 en 3 van dit proefschrift beschrijven methodes om te com-
penseren voor de variatie in houding in CT datasets. In hoofdstuk 4 wordt meer
ingegaan op een gëıntegreerde verwerking van datasets die zijn verkregen met verschil-
lende technieken. Het skelet wordt telkens gebruikt als referentiekader bij het com-
penseren van variaties in houding. Als gevolg is de verwerking van PET-, SPECT-,
MRI-, bioluminescentie- en fluorescentiedata nu nog afhankelijk van een gelijktijdig
verkregen CT dataset. Het verwerken van MRI data is in theorie mogelijk zonder een
CT scan omdat deze datasets naast zacht weefsel contrast ook specifieke informatie
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over het skelet bevatten.
Naast de hierboven beschreven technieken om het effect van behandelingen op
verschillende processen in vivo te beoordelen is het ook belangrijk om de effectiviteit
van stoffen vooraf in vitro te testen. Om te evalueren wat de effecten zijn van stoffen
op de uitgroei van bloedvaten zijn er tal van in vitro tests beschikbaar. De meeste
van deze tests zijn gebaseerd op het meten van de groeisnelheid van endotheel cellen,
bijvoorbeeld HUVECs. Naast de groeisnelheid kan er als maat van angiogenese ook
gekeken worden naar het vermogen van deze cellen om in een driedimensionale matrix
buisachtige structuren te vormen. Angiogenese is echter een complex proces waar
vele celtypes bij betrokken zijn. Bovendien kunnen stoffen niet alleen de uitgroei van
vaten bëınvloeden, maar ook effecten hebben op nieuw gevormde vaten.
In hoofdstuk 5 wordt een in vitro test beschreven die als doel heeft het specifieke
effect van stoffen op bestaande vaten te meten. Deze test is een uitbreiding op een
eerder beschreven test om het effect van stoffen op de uitgroei van bloedvaten te
meten. Beide tests zijn uniek omdat er gebruik wordt gemaakt van ex vivo groeiende
embryonale botjes. Deze botjes bevatten alle celtypes bevatten die betrokken zijn
bij bloedvatgroei. De vaten die uit deze botjes groeien zijn goed te vergelijken met
het soort bloedvaten dat wordt aangetroffen in tumoren omdat in beide gevallen on-
dersteunende cellen en structuren, zoals bijvoorbeeld pericyten en glad spierweefsel,
ontbreken. De test beschreven in hoofdstuk 5 is de eerste test om effecten van stoffen
op bestaande vaten te meten in een systeem waarin diverse celtypes aanwezig zijn.
Zowel de in vitro test voor het meten van effecten van stoffen op bloedvatvorming
en bestaande vaten als de CT analyse methodes zijn gebruikt in hoofdstuk 6 voor
de evaluatie van diverse combinatiebehandelingen van osteolytische botmetastasen
van borstkanker. De combinatiebehandeling is zo samengesteld dat alle relevante
processen voor de groei van botmetastasen in theorie worden geremd. Deze processen
zijn tumorgroei, de uitgroei en vorming van nieuwe bloedvaten en botafbraak. De
combinatiebehandeling bestond uit ENMD-1198 (een 2-methoxyeastradiol (2ME2)-
achige stof), lage dosis cyclofosfamide (CTX), en het bisfosfonaat risedronaat (BP).
2ME2 is een stof die interfereert met de microtubili van het cytoskelet van cellen.
Op die manier werkt 2ME2 antiproliferatief op snel delende cellen zoals kankercellen
en geactiveerde endotheelcellen tijdens angiogenese. Bovendien maakt 2ME2 cellen
gevoeliger voor geprogrammeerde celdood (apoptose). Daarnaast is het aangetoond
dat 2ME2 in vivo de groei van de borstkanker cellijnen 4T1 en MDA-MB-231 kan
remmen. 2ME2 beschermt het bot ook tegen botafbraak. Dit laatste komt door-
dat 2ME2 de differentiatie van nieuwe osteoclasten remt en apoptose veroorzaakt
in bestaande osteoclasten. Het beschermende effect van 2ME2 op het bot is ook
aangetoond in diermodellen voor postmenopauzale osteoporose en postmenopauzale
reumatöıde artritis. ENMD-1198 is een licht gewijzigde vorm van 2ME2 die stabieler
is en een sterkere cytotoxische werking heeft dan 2ME2. De mogelijke effecten van
ENMD-1198 op bot zijn echter nooit onderzocht.
Lage dosis CTX heeft, in tegenstelling tot de traditionele maximum dosis, geen di-
rect effect op de tumorcellen. Lage dosis CTX remt de uitgroei en vorming van nieuwe
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bloedvaten doordat het cytotoxisch is voor geactiveerd endotheel en circulerende en-
dotheliale voorlopercellen. Daarnaast is lage dosis CTX cytotoxisch voor regulatoire
T-cellen. Dit is een celtype dat de immuunrespons kan remmen. Door deze cellen
weg te halen wordt het dus makkelijker om een tumor specifieke immuunrespons te
veroorzaken.
Om de vicieuze cirkel van botafbraak te doorbreken werd in hoofdstuk 6 gebruik
gemaakt van het BP risedronaat. BPs worden in de kliniek gebruikt voor de behan-
deling van bijvoorbeeld osteoporose. BPs binden aan het skelet en remmen vervolgens
de osteoclasten.
In de studie beschreven in hoofdstuk 6 werd in een preklinisch model gebruik
gemaakt van ENMD-1198 bij de behandeling van botmetastasen. In dit model wor-
den botten gëınoculeerd met de bot specifieke osteolytische borstkanker cellijn MDA-
BO2. De MDA-BO2 cellijn is een subkloon van de MDA-MD-231 cellijn, een veel
gebruikt model voor borstkanker. In het hoofdstuk wordt aangetoond dat ENMD-
1198 een gunstig effect heeft op de tumorgroei, bloedvatvorming en botafbraak.
Naast de effecten van ENMD-1198 op de groei van osteolytische botmetastasen
werd er ook gekeken naar het effect van diverse combinatiebehandelingen met ENMD-
1198, CTX en BP. De resultaten beschreven in hoofdstuk 6 laten zien dat de combi-
natiebehandeling van ENMD-1198 en lage dosis CTX niet veel effectiever is dan een
behandeling met ENMD-1198 alleen. Daar dient bij te worden opgemerkt dat deze
experimenten zijn uitgevoerd in een diermodel zonder immuunsysteem terwijl het
werkingsmechanisme van lage dosis CTX wel deels via het immuunsysteem loopt.
Het toevoegen van BP behandeling aan de combinatie leidde niet tot een signifi-
cante verbetering van het behandelingsresultaat. Waarschijnlijk komt dit doordat de
behandeling met ENMD-1198 al een sterk effect op het bot had.
Hoofdstuk 6 is naast de biologische betekenis een voorbeeld van hoe de technieken











APR Articulated Planar Reformation
BLI Bioluminescence Imaging
BMP Bone Morphogenic Protein
BP Bisphosphonate
CA4P Combretastatin Analog A4 Phosphate
CEPs Circulating Endothelial Progenitor Cells
CT Computed Tomography
CTX Cyclophosphamide
CV Coefficient of Variation
EPCs Endothelial Progenitor Cells
FCS Fetal Calf Serum
FGF Fibroblast Growth Factor
FLI Fluorescence Imaging
FMT Fluorescence Molecular Tomography
HE Hematoxylin Eosin
HIF-1α Hypoxia-Inducible Factor-1α
HUVECs Human Umbilical Vein Endothelial Cells
IGF Insulin-Like Growth Factor




MRI Magnetic Resonance Imaging
MTA Microtubule Targeting Agent
NIR Near Infra-Red
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PDGF Platelet Derived Growth Factor
PET Positron Emission Tomography
PTHrP Parathyroid Hormone-Related Protein
RANK Receptor Activator for Nuclear Factor-κB
RANKL Receptor Activator for Nuclear Factor-κB Ligand
ROI Region of Interest
SEER Surveillance Epidemiology and End Results
SEM Standard Error of the Mean
SMA Small Molecule Agents
SNR Signal to Noise Ratio
SPECT Single Photon Emission Computed Tomography
STAT3 Signal Transducer and Activator of Transcription 3
Treg Regulatory T-Cells
TGF-β Transforming Growth Factor-β
TSP-1 Thrombospondin-1
VDA Vascular Disruptive Agent
VEGF Vascular Endothelial Growth Factor
VOI Volume of Interest
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